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 5 
This is the fourth edition of this guideline. The first, published in 2001, was entitled Placenta Praevia: 6 
Diagnosis and Management; the second, published in 2005, was entitled Placenta Praevia and 7 
Placenta Praevia Accreta: Diagnosis and Management; and the third, published in 2011, was entitled 8 
Placenta Praevia, Placenta Praevia Accreta and Vasa Praevia: Diagnosis and Management. 9 
 10 
Executive summary 11 
 12 
Antenatal diagnosis and management of placenta praevia or a low-lying placenta 13 
 14 
What are the risk factors for placenta praevia or a low-lying placenta? 15 
 16 
Caesarean delivery is associated with an increased risk of placenta praevia in subsequent 17 
pregnancies. This risk rises as the number of prior caesarean sections increases. [B] 18 
 19 
Assisted reproductive technology and maternal smoking increase the risk of placenta praevia. [B] 20 
 21 
Should we screen for placenta praevia or a low-lying placenta, if so, at what gestation and with what 22 
follow-up? 23 
 24 
The midpregnancy routine fetal anomaly scan should include placental localisation thereby 25 
identifying women at risk of persisting placenta praevia or a low-lying placenta. [GPP]  26 
 27 
The term placenta praevia should be used when the placenta lies directly over the internal os. For 28 
pregnancies at more than 16 weeks of gestation the term low-lying placenta should be used when 29 
the placental edge is 20 mm or less from the internal os on transabdominal or transvaginal 30 
scanning (TVS). [D] 31 
 32 
If the placenta is thought to be low lying (less than 20 mm from the internal os) or praevia 33 
(covering the os) at the routine fetal anomaly scan, a follow-up ultrasound examination including 34 
a TVS is recommended at 32 weeks of gestation to diagnose persistent low-lying placenta and/or 35 
placenta praevia. [D]  36 
 37 
What is the role and what are the risks of TVS? 38 
 39 
Clinicians should be aware that TVS for the diagnosis of placenta praevia or a low-lying placenta is 40 
superior to transabdominal and transperineal approaches and is safe. [GPP] 41 
 42 
In women with a persistent low-lying placenta or placenta praevia at 32 weeks of gestation who 43 
remain asymptomatic, an additional TVS is recommended at around 36 weeks of gestation to 44 
inform discussion about mode of delivery. [D] 45 
 46 
Cervical length measurement may help facilitate management decisions in asymptomatic women 47 
with placenta praevia. A short cervical length on TVS before 34 weeks of gestation increases the 48 
risk of preterm emergency delivery and massive haemorrhage at caesarean section.  [D]  49 
 50 
Where should women with a low-lying placenta or placenta praevia be cared for in the third 51 
trimester? 52 
 53 
 
 Page 2 of 47 
Women with a low-lying placenta or placenta praevia with recurrent bleeding 54 
 55 
Tailor antenatal care, including hospitalisation, to individual patient need and social 56 
circumstances, e.g. distance between home and hospital and availability of transportation, 57 
previous bleeding episodes, haematology laboratory results and acceptance of receiving donor 58 
blood or blood products. [GPP] 59 
 60 
It should be made clear to any woman being treated at home in the third trimester that she should 61 
attend the hospital immediately if she experiences any bleeding, including spotting, contractions 62 
or pain (including vague suprapubic period-like aches). [GPP] 63 
 64 
Women with asymptomatic placenta praevia or a low-lying placenta 65 
 66 
Women with asymptomatic placenta praevia or a low-lying placenta in the third trimester should 67 
be counselled about the risks of preterm delivery and obstetric haemorrhage, and their care 68 
should be tailored to their individual needs. [GPP] 69 
 70 
Women with asymptomatic placenta praevia confirmed at the 32-week follow-up scan and 71 
managed at home should be encouraged to ensure they have safety precautions in place, including 72 
having someone available to help them as necessary and ready access to the hospital. [GPP] 73 
 74 
Is there a place for cervical cerclage in placenta praevia or a low-lying placenta? 75 
 76 
The use of cervical cerclage to reduce bleeding and prolong pregnancy is not supported by 77 
sufficient evidence to recommend its use outside of a clinical trial. [GPP] 78 
 79 
In what circumstances, and at what gestation, should women be offered antenatal corticosteroids? 80 
 81 
A single course of antenatal corticosteroid therapy is recommended between 34+0 and 36+0 weeks 82 
of gestation for pregnant women with a low-lying placenta or placenta praevia and is appropriate 83 
prior to 34+0 weeks of gestation in women at higher risk of preterm birth. [GPP] 84 
 85 
Is there a place for the use of tocolytics in women presenting with a low-lying placenta or placenta 86 
praevia and preterm labour? 87 
  88 
Tocolysis for women presenting with symptomatic placenta praevia or a low-lying placenta may 89 
be considered for 48 hours to facilitate administration of antenatal corticosteroids. [C] 90 
 91 
Should delivery be indicated based on maternal or fetal concerns, tocolysis should not be used in 92 
attempt to prolong gestation. [C] 93 
 94 
At what gestation should planned delivery occur? 95 
 96 
Late preterm (35+1 to 36+6 weeks of gestation) delivery should be considered for women 97 
presenting with complicated placenta praevia or a low-lying placenta. [C]  98 
 99 
In what situations is vaginal delivery appropriate for women with a low-lying placenta? 100 
 101 
In women with a third trimester asymptomatic low-lying placenta, the mode of delivery should be 102 
based on the clinical background, the woman’s preferences supplemented by ultrasound findings, 103 
including the distance between the placental edge and the fetal head position relative to the 104 
leading edge of the placenta on TVS. [D] 105 
 106 
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Optimising the delivery of placenta praevia 107 
 108 
Prior to delivery, all women with placenta praevia and their partners should have a discussion 109 
regarding delivery. Indications for blood transfusion and hysterectomy should be reviewed and 110 
concerns or plans to decline blood or blood products should be discussed openly and documented. 111 
[GPP]  112 
 113 
Placenta praevia and anterior low-lying placenta carry a higher risk of massive obstetric 114 
haemorrhage and hysterectomy. Delivery should be arranged in a maternity unit with on-site 115 
blood transfusion services and access to critical care. [D]  116 
 117 
Women with atypical antibodies form a particularly high-risk group and the care of these women 118 
should involve discussions with the local haematologist and blood bank. [D] 119 
 120 
Prevention and treatment of anaemia during the antenatal period is recommended for women 121 
with placenta praevia or a low-lying placenta as for any pregnant woman. [D]  122 
 123 
Delivery for women with placenta praevia or a low-lying placenta 124 
 125 
What grade of obstetrician and anaesthetist should attend the caesarean delivery for a placenta 126 
praevia? 127 
 128 
As a minimum requirement for a planned caesarean section for placenta praevia, the surgical 129 
procedure should be carried out by an appropriately experienced operator. [GPP] 130 
 131 
In cases of planned caesarean section for placenta praevia or a low-lying placenta, a senior 132 
obstetrician (usually a consultant) and senior anaesthetist (usually a consultant) should be present 133 
within the delivery or theatre suite where the surgery is occurring. [GPP]  134 
 135 
When an emergency arises, the senior obstetrician and senior anaesthetist should be alerted 136 
immediately and attend urgently. [GPP]  137 
 138 
What anaesthetic procedure is most appropriate for caesarean section in placenta praevia or a low-139 
lying placenta? 140 
 141 
Regional anaesthesia is considered safe and associated with lower risks of haemorrhage than 142 
general anaesthesia for caesarean delivery in women with placenta praevia or a low-lying 143 
placenta. Women with anterior placenta praevia or a low-lying placenta should be advised that it 144 
may be necessary to convert to general anaesthesia if required and asked to consent. [D] 145 
 146 
What blood products should be available? 147 
 148 
Close liaison with the hospital transfusion laboratory is essential for women presenting with 149 
placenta praevia or a low-lying placenta. [GPP] 150 
 151 
Rapid infusion and fluid warming devices should be immediately available. [GPP] 152 
 153 
Cell salvage is recommended for patients where the anticipated blood loss is great enough to 154 
induce anaemia, in particular, in women who would decline blood products. [D] 155 
 156 
What surgical approach should be used for placenta praevia or a low-lying placenta? 157 
 158 
Consider vertical skin and/or uterine incisions when the fetus is in a transverse lie to avoid the 159 
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placenta, particularly below 28 weeks of gestation. [GPP] 160 
 161 
Consider using preoperative and/or intraoperative ultrasonography to precisely determine 162 
placental location and the optimal place for uterine incision. [D] 163 
 164 
If the placenta is transected during the uterine incision, immediately clamp the umbilical cord 165 
after fetal delivery to avoid excessive fetal blood loss. [D] 166 
 167 
If pharmacological measures fail to control haemorrhage, initiate intrauterine tamponade and/or 168 
surgical haemostatic techniques sooner rather than later. Interventional radiological techniques 169 
should also be urgently employed where possible. [C] 170 
 171 
Early recourse to hysterectomy is recommended if conservative medical and surgical interventions 172 
prove ineffective. [D]  173 
 174 
Antenatal diagnosis and outcome of placenta accreta spectrum  175 
 176 
What are the risk factors for placenta accreta spectrum? 177 
 178 
The major risk factors for placenta accreta spectrum are history of accreta in a previous 179 
pregnancy, previous caesarean delivery and other uterine surgery, including repeated endometrial 180 
curettage. This risk rises as the number of prior caesarean sections increases. [B] 181 
 182 
Women requesting elective caesarean delivery for non-medical indications should be informed of 183 
the risk of placenta accreta spectrum and its consequences for subsequent pregnancies. [GPP] 184 
 185 
How can a placenta accreta spectrum be suspected and diagnosed antenatally? 186 
 187 
Antenatal diagnosis of placenta accreta spectrum is crucial in planning its management and has 188 
been shown to reduce maternal morbidity and mortality. [D] 189 
 190 
Previous caesarean delivery and the presence of an anterior low-lying placenta or placenta praevia 191 
should alert the antenatal care team of the higher risk of placenta accreta spectrum. [D] 192 
 193 
Ultrasound screening and diagnosis of placenta accreta spectrum 194 
 195 
Ultrasound imaging is highly accurate when performed by a skilled operator with experience in 196 
diagnosing placenta accreta spectrum. [C] 197 
 198 
Refer women with any ultrasound features suggestive of placenta accreta spectrum to a specialist 199 
unit with imaging expertise. [B] 200 
 201 
Women with a history of previous caesarean section seen to have an anterior low-lying placenta 202 
or placenta praevia at the routine fetal anomaly scan should be specifically screened for placenta 203 
accreta spectrum. [D] 204 
 205 
Is there a role for magnetic resonance imaging (MRI) in the diagnosis of placenta accreta spectrum? 206 
 207 
Clinicians should be aware that the diagnostic value of MRI and ultrasound imaging in detecting 208 
placenta accreta spectrum is similar when performed by experts. [C] 209 
 210 
MRI may be used to complement ultrasound imaging to assess the depth of invasion and lateral 211 
extension of myometrial invasion, especially with posterior placentation and/or in women with 212 
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ultrasound signs suggesting parametrial invasion. [GPP] 213 
 214 
Where should women with placenta accreta spectrum be cared for? 215 
 216 
Women diagnosed with placenta accreta spectrum should be cared for by a multidisciplinary team 217 
in a specialist centre with expertise in diagnosing and managing invasive placentation. [GPP] 218 
 219 
Delivery for women diagnosed with placenta accreta spectrum should take place in a specialist 220 
centre with logistic support for immediate access to blood products, adult intensive care unit and 221 
neonatal intensive care unit (NICU) by a multidisciplinary team with expertise in complex pelvic 222 
surgery. [D] 223 
 224 
When should delivery be planned for women with placenta accreta spectrum? 225 
 226 
In the absence of risk factors for preterm delivery and evidence of invasive placentation, planned 227 
delivery at 35+0 to 36+6 weeks of gestation provides the best balance between fetal maturity and 228 
the risk of unscheduled delivery. [GPP] 229 
 230 
Planning delivery of a suspected placenta accreta spectrum 231 
 232 
Once the diagnosis of placenta accreta spectrum is made, a contingency plan for emergency 233 
delivery should be developed, including the use of an institutional protocol for the management of 234 
maternal haemorrhage. [GPP] 235 
 236 
What should be included in the consent form for caesarean section in cases of suspected placenta 237 
accreta spectrum? 238 
 239 
Any woman giving consent for caesarean section should understand the risks associated with 240 
caesarean section in general, and the specific risks of placenta accreta spectrum in terms of 241 
massive obstetric haemorrhage, increased risk of lower urinary tract damage, the need for blood 242 
transfusion and the risk of hysterectomy. [GPP] 243 
 244 
Additional possible interventions in the case of massive haemorrhage should also be discussed, 245 
including cell salvage and interventional radiology where available. [D] 246 
 247 
What healthcare professionals should be involved? 248 
 249 
The elective delivery of women with placenta accreta spectrum should be managed by a 250 
multidisciplinary team, which should include senior anaesthetists, obstetricians and 251 
gynaecologists with appropriate experience in managing the condition and other surgical 252 
specialties if indicated. In an emergency, the most senior clinicians available should be involved. 253 
[GPP] 254 
 255 
What anaesthetic is most appropriate for delivery? 256 
 257 
The choice of anaesthetic technique for caesarean section for placenta accreta spectrum should be 258 
made by the anaesthetist conducting the procedure in consultation with the patient in advance. 259 
[GPP] 260 
 261 
The woman should be informed that the surgical procedure can be performed safely with regional 262 
anaesthesia but should be advised that it may be necessary to convert to general anaesthesia if 263 
required and asked to consent. [D] 264 
 265 
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Optimising the delivery of placenta accreta spectrum 266 
 267 
What surgical approach should be used for placenta accreta spectrum? 268 
 269 
Caesarean section hysterectomy with the placenta left in situ is preferable to attempting to 270 
separate it from the uterine wall. [C] 271 
 272 
When the extent of the placenta accreta is limited in depth and surface area, and the entire 273 
placental implantation area is accessible and visualised (i.e. completely anterior, fundal or 274 
posterior without deep pelvic invasion), uterus-preserving surgery may be appropriate, including 275 
partial myometrial resection. [GPP] 276 
 277 
Uterus-preserving surgical techniques should only be attempted by surgeons working in teams 278 
with appropriate expertise to manage such cases and after appropriate counselling regarding risks 279 
and with informed consent. [D] 280 
 281 
There are currently insufficient data to recommend the routine use of ureteric stents in placenta 282 
creta and increta. [C] 283 
 284 
What surgical approach should be used for placenta percreta? 285 
 286 
There is limited evidence to support uterus-preserving surgery in placenta percreta and women 287 
should be informed of the high risk of peripartum and secondary complications, including the 288 
need for secondary hysterectomy. [D] 289 
 290 
Expectant management (leaving the placenta in situ) 291 
 292 
Elective peripartum hysterectomy may be unacceptable to women desiring uterine preservation 293 
or considered inappropriate by the surgical team. In such cases, leaving the placenta in situ should 294 
be considered. [D] 295 
 296 
When the placenta is left in situ, local arrangements need to be made to ensure regular review, 297 
ultrasound examination and access to emergency care should the woman experience 298 
complications, such as bleeding or infection. [D] 299 
 300 
Methotrexate (MTX) adjuvant therapy should not be used for expectant management as it is of 301 
unproven benefit and has significant adverse effects, including a reported maternal death. [C] 302 
 303 
When is interventional radiology indicated? 304 
 305 
Larger studies are necessary to determine the safety and efficacy of interventional radiology 306 
before this technique can be advised in the routine management of placenta accreta spectrum. [D] 307 
 308 
Women diagnosed with placenta accreta spectrum who decline donor blood transfusion should be 309 
managed in a unit with an interventional radiology service. [D] 310 
 311 
How is unsuspected placenta accreta spectrum at delivery best managed? 312 
 313 
If at the time of an elective repeat caesarean section, where both mother and baby are stable, it is 314 
immediately apparent that placenta percreta is present on opening the abdomen, the caesarean 315 
section should be delayed until the appropriate staff and resources have been assembled and 316 
adequate blood products are available. This may involve closure of the maternal abdomen and 317 
urgent transfer to a specialist unit for delivery. [GPP] 318 
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 319 
In case of unsuspected placenta accreta spectrum diagnosed after delivery of the baby, the 320 
placenta should be left in situ and an emergency hysterectomy performed. [D]  321 
 322 
1. Purpose and scope 323 
 324 
The purpose of this guideline is to describe the diagnostic modalities and review the evidence-based 325 
approach to the clinical management of pregnancies complicated by placenta praevia and placenta 326 
accreta. 327 
 328 
2. Introduction and background epidemiology  329 
 330 
Placenta praevia and placenta accreta are associated with high maternal and neonatal morbidity and 331 
mortality.1–5 The rates of placenta praevia and accreta have increased and will continue to do so as a 332 
result of rising rates of caesarean deliveries, increased maternal age and use of assisted reproductive 333 
technology (ART), placing greater demands on maternity-related resources. The highest rates of 334 
complication for both mother and newborn are observed when these conditions are only diagnosed 335 
at delivery. 336 
 337 
2.1 Placenta praevia  338 
 339 
Determining placental location is one of the first aims of routine midpregnancy (18+6–21+6 weeks of 340 
gestation) transabdominal obstetric ultrasound examination.6,7 Placenta praevia was originally 341 
defined using transabdominal scan as a placenta developing within the lower uterine segment and 342 
graded according to the relationship and/or the distance between the lower placental edge and the 343 
internal os of the uterine cervix. Grade I or minor praevia was defined as a lower edge inside the 344 
lower uterine segment; grade II or marginal praevia as a lower edge reaching the internal os; grade 345 
III or partial praevia when the placenta partially covers the cervix; and grade IV or complete praevia 346 
when the placenta completely covers the cervix. Grades I and II are also often defined as ’minor’ 347 
placenta praevia whereas grades III and IV are referred to as ’major’ placenta praevia.  348 
 349 
The introduction of transvaginal scanning (TVS) in obstetrics in the 1980s has allowed for a more 350 
precise evaluation of the distance between the placental edge and the internal os. A recent 351 
multidisciplinary workshop of the American Institute of Ultrasound in Medicine (AIUM)8 has 352 
recommended discontinuing the use of the terms ‘partial’ and ‘marginal’, suggesting that the term 353 
‘placenta praevia’ is used when the placenta lies directly over the internal os. For pregnancies 354 
greater than 16 weeks of gestation, the placenta should be reported as ‘low lying’ when the 355 
placental edge is less than 20 mm from the internal os and as normal when the placental edge is 20 356 
mm or more from the internal os on transabdominal or TVS. This new classification could better 357 
define the risks of perinatal complications, such as antepartum haemorrhage and major postpartum 358 
haemorrhage (PPH),9,10 and has the potential of improving the obstetric management of placenta 359 
praevia. Recent articles reviewed in this guideline refer to the AIUM classification. 360 
 361 
The estimated incidence of placenta praevia at term is 1 in 200 pregnancies.5,9 However, this is 362 
dependent on the definition used and is likely to change with the introduction of the AIUM 363 
classification described above and with the rising incidence of the main risk factors, i.e. prior 364 
caesarean delivery and pregnancies resulting from ART. The relationship between a low-lying 365 
placenta or placenta praevia and a velamentous insertion of the umbilical cord is presented and 366 
discussed in sister Green-top Guideline no. 27b: Vasa Praevia: Diagnosis and Management.  367 
 368 
2.2 Placenta accreta 369 
 370 
Placenta accreta is a histopathological term first defined by Irving and Hertig in 1937, as the 371 
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“abnormal adherence of the afterbirth in whole or in parts to the underlying uterine wall in the 372 
partial or complete absence of decidua”.11 Irving and Hertig did not include abnormally invasive 373 
placentation in their series and thus in their description was limited to abnormally adherent 374 
placenta. Depending on the depth of villous tissue invasiveness, placenta accreta was subsequently 375 
subdivided by modern pathologists into ‘creta’ or ‘adherenta’ where the villi adheres superficially to 376 
the myometrium without interposing decidua; ‘increta’ where the villi penetrate deeply into the 377 
uterine myometrium down to the serosa; and ‘percreta’ where the villous tissue perforates through 378 
the entire uterine wall and may invade the surrounding pelvic organs, such as the bladder.12-14 Cases 379 
of placenta accreta are also often subdivided into total, partial or focal according to the amount of 380 
placental tissue involved and the different depths of accreta placentation have been found to co-381 
exist in the same case.12,15 Thus placenta accreta is a spectrum disorder ranging from abnormally 382 
adherent to deeply invasive placental tissue.  383 
 384 
Detailed data on clinical findings and, where possible, on histopathological examination are essential 385 
when describing different diagnostic or management techniques.16,17 The diagnostic conundrum is 386 
obvious at the abnormally adherent end of the spectrum where the differential diagnosis between a 387 
difficult manual removal and an abnormally adherent or placenta accreta may be impossible in the 388 
absence of histopathological confirmation. These diagnostic difficulties probably explain the current 389 
wide variation in reported prevalence of placenta accreta ranging between 1 in 300 and 1 in 2000 390 
pregnancies1–5 and highlight the need for a standardised approach to imaging, clinical and 391 
histopathological descriptions. In the last decade, even the condition itself has begun to be known 392 
by many different names, with ‘morbidly adherent placenta’ becoming particularly popular. This 393 
terminology was originally used in the 19th century to describe the clinical complications associated 394 
with a retained placenta. This terminology is misleading as ‘morbidly adherent’ does not encompass 395 
the abnormally invasive end of the accreta spectrum (increta and percreta), which usually have the 396 
worst clinical outcomes.16,17 In order to overcome these difficulties, the terms ‘placenta accreta 397 
spectrum’ or ’abnormally adherent and invasive placenta’ should be used to include both the 398 
abnormally adherent and invasive forms of accreta placentation.18 In this guideline, the term 399 
placenta accreta spectrum will be used. 400 
 401 
In the 1990s, the maternal mortality of placenta percreta was reported to be as high as 7% of 402 
cases.19 More recent large series have reported lower rates of maternal death and this is likely to be 403 
further improved by screening for placenta accreta spectrum in women at high risk and in planning 404 
the delivery in specialist centres.20–22  405 
 406 
3. Identification and assessment of evidence 407 
 408 
This guideline was developed in accordance with standard methodology for producing Royal College 409 
of Obstetricians and Gynaecologists (RCOG) Green-top Guidelines. The Cochrane Library (including 410 
the Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effects 411 
[DARE]), EMBASE, Trip, MEDLINE and PubMed (electronic databases) were searched for relevant 412 
randomised controlled trials (RCT), systematic reviews and meta-analyses. The search was restricted 413 
to articles published between May 2009 and December 2017 (the search for the previous Guideline 414 
was up to May 2009). The databases were searched using the relevant Medical Subject Headings 415 
(MeSH) terms, including all subheadings, and this was combined with a keyword search. Search 416 
words included ‘placenta praevia’, ‘low lying placenta’, ‘placenta accreta’, ‘placenta increta’ 417 
‘placenta percreta’, ‘abnormally adherent placenta’ and ‘abnormally invasive placenta’. The search 418 
was restricted to humans and the English language. The National Library for Health and the National 419 
Guideline Clearinghouse were also searched for relevant guidelines and reviews. 420 
 421 
Where possible, recommendations are based on available evidence. In the absence of published 422 
evidence, these have been annotated as ‘good practice points’. Further information about the 423 
assessment of evidence and the grading of recommendations may be found in Appendix I. 424 
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 425 
4. Antenatal diagnosis and management of placenta praevia or a low-lying placenta 426 
 427 
4.1 What are the risk factors for placenta praevia or a low-lying placenta? 428 
 429 
Caesarean delivery is associated with an increased risk of placenta praevia in subsequent 430 
pregnancies. This risk rises as the number of prior caesarean sections increases. [B] 431 
 432 
ART and maternal smoking increase the risk of placenta praevia. [B] 433 
 434 
In 1997, a meta-analysis of the association of placenta praevia with history of caesarean delivery 435 
found a dose-response pattern for the relative risk (RR) of placenta praevia of 4.5 (95% CI 3.6–5.5) 436 
for one, 7.4 (95% CI 7.1–7.7) for two, 6.5 (95% CI 3.6–11.6) for three, and 44.9 (95% CI 13.5–149.5) 437 
for four or more prior caesarean deliveries compared with vaginal delivery.23 [Evidence level 2++] 438 
 439 
A systematic review and meta-analysis of 22 studies including over 2 million deliveries indicated that 440 
the incidence of placenta praevia increases from 10 in 1000 deliveries with one previous caesarean 441 
delivery to 28 in 1000 with three or more caesarean deliveries.24 A 2014 meta-analysis confirmed 442 
these findings and reported an overall odds ratio (OR) of 1.47 (95% CI 1.44–1.51) for placenta 443 
praevia after caesarean section.25 [Evidence level 1+] 444 
 445 
Cohort studies have also reported that a second pregnancy within 1 year of a caesarean section is 446 
associated with an increased risk of placenta praevia (RR 1.7, 95% CI 0.9–3.1).26 Compared with 447 
vaginal birth, a previous prelabour caesarean section is associated with an increased risk of placenta 448 
praevia in the second delivery (adjusted OR [aOR] 2.62, 95% CI 1.24–5.56).27 [Evidence level 2++] 449 
 450 
There have been contradictory reports regarding the incidence of placenta praevia in multiple 451 
pregnancies. A retrospective cohort study of 1 172 405 twin live births and stillbirths in the USA 452 
between 1989 and 1998 found no increased risk in twins.28 A retrospective cohort of 67 895 453 
singleton and twin pregnancies found that dichorionic (aOR 1.54, 95% CI 1.15–2.06) and 454 
monochorionic (RR 3.29, 95% CI 1.32–8.21) twin pregnancies had an increased risk of placenta 455 
praevia compared with singletons.29 [Evidence level 2+] 456 
 457 
ART is associated with a higher incidence of placenta praevia independently of the high rate of 458 
multiple pregnancies generated by the technique used.30,31 A 2016 meta-analysis of ART singleton 459 
pregnancies reported a RR of 3.71 (95% CI 2.67–5.16) for placenta praevia32 that was confirmed by a 460 
2017 meta-analysis (OR 2.67, 95% CI 2.01–3.34).33 Furthermore, a 2017 meta-analysis of the impact 461 
of maternal smoking on placental position34 (OR 1.42, 95% CI 1.30–1.50) has found an increased risk 462 
of  placenta praevia. [Evidence level 1+] 463 
 464 
Advanced maternal age has been also associated with a slight increase in the risk of placenta praevia 465 
(OR 1.08, 95% CI 1.07–1.09) but this effect may be due to parity 35. [Evidence level 2–] 466 
 467 
4.2 Should we screen for placenta praevia or a low-lying placenta, if so, at what gestation and with 468 
what follow-up? 469 
 470 
The midpregnancy routine fetal anomaly scan should include placental localisation thereby 471 
identifying women at risk of persisting placenta praevia or a low-lying placenta. [GPP]  472 
 473 
The term placenta praevia should be used when the placenta lies directly over the internal os. For 474 
pregnancies at more than 16 weeks of gestation the term low-lying placenta should be used when 475 
the placental edge is 20 mm or less from the internal os on transabdominal or TVS. [D] 476 
 477 
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If the placenta is thought to be low lying (less than 20 mm from the internal os) or praevia 478 
(covering the os) at the routine fetal anomaly scan, a follow-up ultrasound examination including 479 
a TVS is recommended at 32 weeks of gestation to diagnose persistent low-lying placenta and/or 480 
placenta praevia. [D]  481 
  482 
Placenta praevia is a well-established complication of pregnancy associated with high maternal and 483 
perinatal complication rates.4–9 The UK National Screening Committee (UK NSC) does not 484 
recommend a national screening program for placenta praevia, but it has supported current local 485 
practices of identifying it at the routine midpregnancy (18+6–21+6 weeks of gestation) antenatal 486 
screening ultrasound examination in women whose placenta extends onto the internal cervical os 487 
(www.screening.nhs.uk/policies).36 An update published in 2014 that included a literature search 488 
covering the period between January 2008 and November 2012 concluded that this practice was not 489 
supported by new evidence, but that the placental site is routinely reported at the time of the 490 
routine fetal anomaly scan. In turn, this routine study has become the main screening test for 491 
placenta praevia.37 [Evidence level 4] 492 
 493 
Apparent placental ‘migration’ following the development of the lower uterine segment during the 494 
third trimester of pregnancy results in the resolution of the low-lying placenta in 90% of the cases 495 
before term.38–46 This is less likely to occur in women with a previous caesarean delivery.39 [Evidence 496 
level 4] 497 
 498 
In twin pregnancies, the likelihood of persistence of placenta praevia is also dependent on the 499 
gestational age at sonographic detection. Among those with placenta praevia diagnosed in the 500 
second trimester the majority of cases resolve by 32 weeks of gestation.29,47 After 32 weeks of 501 
gestation around 50% of the remaining placenta praevia will resolve, with no further changes after 502 
36 weeks of gestation.29 [Evidence level 3] 503 
 504 
The timing of a confirmatory ultrasound examination in the third trimester has varied between 32 505 
and 36 weeks of gestation depending on the extent of the placenta praevia over the internal cervical 506 
os. It is based on the perceived risk of antenatal haemorrhage, but there is no strong evidence that it 507 
makes a difference in the care of asymptomatic women.37 The timing of the follow-up ultrasound 508 
examination should also be tailored according to a previous history of caesarean delivery to exclude 509 
an associated placenta accreta spectrum. [Evidence level 4] 510 
 511 
4.3 What is the role and what are the risks of TVS? 512 
 513 
Clinicians should be aware that TVS for the diagnosis of placenta praevia or a low-lying placenta is 514 
superior to transabdominal and transperineal approaches and is safe. [GPP] 515 
 516 
In women with a persistent low-lying placenta or placenta praevia at 32 weeks of gestation who 517 
remain asymptomatic, an additional TVS is recommended at around 36 weeks of gestation to 518 
inform discussion about mode of delivery. [D] 519 
 520 
Cervical length measurement may help facilitate management decisions in asymptomatic women 521 
with placenta praevia. A short cervical length on TVS before 34 weeks of gestation increases the 522 
risk of preterm emergency delivery and massive haemorrhage at caesarean section. [D]  523 
 524 
TVS improves the accuracy of placental localisation particularly when the placenta is posterior or if 525 
the transabdominal ultrasound is unclear, for example, due to maternal obesity or the presence of 526 
large uterine fibroids.5 [Evidence level 4] 527 
 528 
There is only one small (n = 38) RCT comparing transabdominal scan and TVS for placenta praevia, 529 
which supports this safety profile and reports superior views, especially for posterior placentas.48 530 
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[Evidence level 1+] 531 
 532 
If the distance between the internal os and the placental edge is 20 mm or more on TVS, the 533 
placental location should be recorded as normal and managed as per routine. Studies have not 534 
demonstrated an increased risk for caesarean section due to haemorrhage in these cases.4,5 By 535 
contrast, if the placenta extends beyond the internal os on TVS during the second trimester, it is 536 
likely to be confirmed as placenta praevia at 32 weeks of gestation.48–50  However, ‘migration’ is still 537 
possible after 32 weeks of gestation.50,51 [Evidence level 2+] 538 
 539 
TVS will reclassify 26–60% of placentas diagnosed as low lying at the routine fetal anomaly scan.52–54 540 
Overall, TVS has a high accuracy (positive predictive value of 93.3%, negative predictive value of 541 
97.6% and false-negative rate of 2.33%) in predicting placenta praevia in women suspected of having 542 
a low-lying placenta on transabdominal scan in the second and early third trimester, with a 543 
sensitivity of 87.5% and a specificity of 98.8%.55 [Evidence level 2+] 544 
 545 
TVS has also been used to measure the cervical length to predict preterm birth56 and cohort studies 546 
with low risks of confounding bias have shown that cervical length is a predictor of antepartum 547 
bleeding and emergency preterm caesarean section in placenta praevia.57–60 A prospective cohort 548 
study of 59 women presenting with placenta praevia covering the internal os has shown that the 549 
best cut-off point for the identification of women at risk of haemorrhage requiring a caesarean 550 
delivery before 34 weeks of gestation is a cervical length of 31 mm or less (sensitivity of 83.3% and 551 
specificity of 76.6%). Women with a cervical length of less than 31 mm have a 16 times (OR 16.4; 552 
95% CI 3.4–75.9) higher risk of emergency caesarean section due to massive haemorrhage.57 553 
Similarly, a prospective cohort study of 54 women with placenta praevia covering the internal os has 554 
shown that combining a cervical length of less than 30 mm and measurement of the lower placental 555 
edge thickness of more than 10 mm has a sensitivity of 83.3% and a specificity of 78.4%.58 More 556 
prospective studies using a standardised ultrasound definition of placental edge thickness are 557 
required before this sign can be used in clinical practice. [Evidence level 2+]  558 
 559 
Compared with women with a long cervical length, women with a short cervical length (less than 25 560 
mm) have a RR of 7.2 (95% CI 2.3–22.3) for massive haemorrhage during caesarean section for 561 
placenta praevia.59 [Evidence level 2+]  562 
 563 
Serial TVS cervical length measurements from 26 weeks of gestation have indicated that when the 564 
length of the cervix decreases rapidly to 35 mm or less there is an increased risk of preterm 565 
caesarean section due to massive haemorrhage.60 [Evidence level 2–]  566 
 567 
4.4 Where should women with a low-lying placenta or placenta praevia be cared for in the third 568 
trimester? 569 
 570 
4.4.1 Women with a low-lying placenta or placenta praevia with recurrent bleeding 571 
 572 
Tailor antenatal care, including hospitalisation, to individual patient need and social 573 
circumstances, e.g. distance between home and hospital and availability of transportation, 574 
previous bleeding episodes, haematology laboratory results and acceptance of receiving donor 575 
blood or blood products. [GPP] 576 
 577 
Where hospital admission has been decided, a documented assessment of risk factors for VTE in 578 
pregnancy should be performed as outlined in RCOG GTG No. 37a. [D] 579 
 580 
It should be made clear to any woman being treated at home in the third trimester that she should 581 
attend the hospital immediately if she experiences any bleeding, including spotting, contractions 582 
or pain (including vague suprapubic period-like aches). [GPP] 583 
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 584 
The Cochrane systematic review by Nielson on the impact of an intervention in women diagnosed as 585 
having, or being likely to have a placenta praevia, which has not been updated since October 2002, 586 
includes only one small RCT (n = 53) comparing hospital versus home care for symptomatic placenta 587 
praevia.61 This trial found little evidence of any clear advantage or disadvantage to a policy of home 588 
versus hospital care, and the only significant difference was a reduction in length of hospital stay.62 589 
[Evidence level 1–] 590 
 591 
Two large retrospective studies of women presenting with placenta praevia at the routine fetal 592 
anomaly scan have proposed scores to predict the risk of emergency caesarean section. The first 593 
study (n = 250) found that the risk is increased if the first (sentinel) vaginal bleeding episode occurs 594 
before 29 weeks of gestation (OR 2.64, 95% CI 1.17–5.98), and with the occurrence of three or more 595 
episodes of antepartum haemorrhage (OR 2.53, 95% CI 1.1–5.86).63 The second (n = 214) found that 596 
independent predictors for emergency delivery are a history of caesarean section (OR 4.7, 95 CI 1.2–597 
12); antepartum haemorrhage on one (OR 7.5, 95% CI 2.5–23), two (OR 14, 95% CI 4.3–47), and 598 
three or more occasions (OR 27, 95% CI 8.3–90); and need for antenatal blood transfusion (OR 6.4, 599 
95% CI 1.7–23).10 A retrospective study of 214 women with singleton pregnancies found that the risk 600 
of preterm emergency caesarean delivery increases with the number of antepartum bleeding 601 
episodes with one (OR 7.5, 95% C, 2.5-23), two (OR 14, 95% CI 4.3-47), and three or more (OR 27, 602 
95% CI 8.3-90), as well as need for blood transfusion (OR 6.4, 95% C, 1.7-23).64 The results of these 603 
studies suggest that predictors for emergency delivery in women with placenta praevia can be used 604 
for individualised antenatal care regarding need for hospital admission, corticosteroids 605 
administration and timing of delivery. [Evidence level 2–] 606 
 607 
4.4.2 Women with asymptomatic placenta praevia or a low-lying placenta  608 
 609 
Women with asymptomatic placenta praevia or a low-lying placenta in the third trimester should 610 
be counselled about the risks of preterm delivery and obstetric haemorrhage, and their care 611 
should be tailored to their individual needs. [GPP] 612 
 613 
Women with asymptomatic placenta praevia confirmed at the 32-week follow-up scan and 614 
managed at home should be encouraged to ensure they have safety precautions in place, including 615 
having someone available to help them as necessary and ready access to the hospital. [GPP] 616 
 617 
Most women with asymptomatic placenta praevia (no bleeding or contractions) can be cared for as 618 
outpatients with similar outcomes compared with hospitalisation and at lower cost.5 Numerous 619 
factors influence the chances of the placenta praevia persisting until delivery, such as prior 620 
caesarean section,43 the distance between the placental edge and the internal os, and the thickness 621 
of the placental edge.4 These parameters can be useful in tailoring individual patient needs. 622 
[Evidence level 4] 623 
 624 
4.5 Is there a place for cervical cerclage in placenta praevia or a low-lying placenta? 625 
 626 
The use of cervical cerclage to reduce bleeding and prolong pregnancy is not supported by 627 
sufficient evidence to recommend its use outside of a clinical trial. [GPP] 628 
 629 
The Cochrane systematic review by Nielson61 on the impact of cerclage in women diagnosed as 630 
having, or being likely to have, placenta praevia included two small RCTs (n = 25 and 36) comparing 631 
cervical cerclage versus no cerclage. There may be a reduction in preterm births before 34 weeks of 632 
gestation (RR 0.45, 95% CI 0.23–0.87), but this evidence is not robust enough to recommend its use 633 
outside of clinical trials. [Evidence level 1–] 634 
 635 
There have been no new trials looking at this issue since the last update of this guideline. 636 
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 637 
4.6 In what circumstances, and at what gestation, should women be offered antenatal 638 
corticosteroids? 639 
 640 
A single course of antenatal corticosteroid therapy is recommended between 34+0 and 36+0 weeks 641 
of gestation for pregnant women with a low-lying placenta or placenta praevia and is appropriate 642 
prior to 34+0 weeks of gestation in women at higher risk of preterm birth. [GPP] 643 
 644 
A large case–control study found that neonatal morbidities in women with placenta praevia include 645 
an increased risk of lower 5-minute Apgar scores, neonatal intensive care unit (NICU) admission, 646 
anaemia, respiratory distress syndrome, mechanical ventilation and intraventricular haemorrhage.65 647 
Neonates born to mothers with placenta praevia have lower birthweights (2806 versus 3285 g) and 648 
lower gestational ages (36+2 versus 38+1 weeks). These differences were not significant after 649 
adjusting for confounders such as prematurity.66 [Evidence level 2++] 650 
 651 
Compared with placebo or no treatment with antenatal corticosteroids (betamethasone, 652 
dexamethasone or hydrocortisone), antenatal corticosteroids are associated with a reduction in the 653 
most serious adverse outcomes related to prematurity, including perinatal death (RR 0.72, 95% CI 654 
0.58–0.89), respiratory distress syndrome (average RR 0.66, 95% CI 0.56–0.77), intraventricular 655 
haemorrhage (average RR 0.55, 95% CI 0.40–0.76) and necrotising enterocolitis (RR 0.50, 95% CI 656 
0.32–0.78).67 [Evidence level 1+] 657 
 658 
The 2016 RCT has found that the administration of betamethasone to women with a singleton 659 
pregnancy at risk for late preterm delivery (34+0 to 36+5 weeks of gestation) significantly reduces the 660 
rate of neonatal respiratory complications.68 [Evidence level 1+] 661 
 662 
A decision analytic model designed to compare total maternal and neonatal quality-adjusted life 663 
years for delivery of women with placenta praevia at 34+0 to 36+6 weeks of gestation indicated that 664 
corticosteroids administration at 35+5 weeks of gestation followed by planned delivery at 36 weeks 665 
of gestation optimises maternal and neonatal outcomes.69 [Evidence level 4] 666 
 667 
4.7 Is there a place for the use of tocolytics in women presenting with a low-lying placenta or 668 
placenta praevia and preterm labour? 669 
  670 
Tocolysis for women presenting with symptomatic placenta praevia or a low-lying placenta may 671 
be considered for 48 hours to facilitate administration of antenatal corticosteroids. [C] 672 
 673 
Should delivery be indicated based on maternal or fetal concerns, tocolysis should not be used in 674 
attempt to prolong gestation. [C]  675 
A systematic review to determine if the prolonged (48 hours or more) use of tocolytics in women 676 
with symptomatic preterm placenta praevia improves perinatal outcome identified two 677 
retrospective studies (total, n = 217) and one RCT (n = 60).70 The results of the RCT showed that 678 
pregnancy can be prolonged for more than 7 days with continued tocolytics (OR 3.10, 95% CI 1.38–679 
6.96). When combined with the data of retrospective studies, the results did not reach significance 680 
(OR 1.19, 95% CI 0.63–2.28). The RCT was judged inadequately compliant with the Consolidated 681 
Standards of Reporting Trials statement. [Evidence level 1–] 682 
 683 
A recent randomised, double-blind, placebo-controlled multicentre trial including 109 women at 24+0 684 
to 33+6 weeks with at least one episode of placenta praevia bleeding and intact membranes has 685 
shown that there is no difference in the prolongation of pregnancy between the nifedipine (n = 54) 686 
and placebo (n = 55) groups.71 Adverse perinatal outcomes were comparable between groups. 687 
[Evidence level 1+] 688 
 689 
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4.8 At what gestation should planned delivery occur? 690 
 691 
Delivery timing should be tailored according to antenatal symptoms and for women presenting 692 
with uncomplicated placenta praevia delivery should be considered between 36 and 37 weeks of 693 
gestation. [C]  694 
 695 
As the risk of major haemorrhage increases rapidly after 36 weeks of gestation, expert opinions have 696 
highlighted that decisions regarding timing of delivery must be individualised and suggested that on 697 
the basis of limited data available, women with uncomplicated placenta praevia should undergo 698 
scheduled birth by caesarean section between 36 and 37 weeks of gestation.69,72,73 [Evidence level 4] 699 
 700 
The risks of bleeding, labour, or bleeding and labour leading to the need for emergency delivery 701 
increase with advancing gestational age, whereas the risks of morbidity associated with prematurity 702 
decrease.4,5 The risk of an emergent bleed associated with placenta praevia has been reported to be 703 
4.7% by 35 weeks of gestation, 15% by 36 weeks of gestation, 30% by 37 weeks of gestation and 59% 704 
by 38 weeks of gestation.74 [Evidence level 2–] 705 
 706 
A US population-based cohort study using the Centre for Disease Control and Prevention’s Linked 707 
Birth-Infant Death data files has evaluated the effects of delivering placenta praevia at 35, 36 and 37 708 
weeks of gestation on the risk of several neonatal outcomes.75 Compared with neonates born at 38 709 
weeks of gestation, those delivered at 35, 36 and 37 weeks of gestation have no greater odds of 710 
meconium passage, fetal distress, fetal anaemia, neonatal seizures, increased ventilator needs or 711 
infant death at 1 year. However, aOR odds of 5-minute Apgar scores of less than 7 are greater at 35 712 
and 36 weeks of gestation (aOR 3.33, 95% CI 1.71–6.47; and aOR 2.17, 1.11–4.22, respectively) as 713 
are odds of NICU admission rates (aOR 2.25, 95% CI 2.01–2.50; and aOR 1.57, 1.38–1.76, 714 
respectively). [Evidence level 2+] 715 
 716 
4.9 In what situations is vaginal delivery appropriate for women with a low-lying placenta? 717 
 718 
In women with a third trimester asymptomatic low-lying placenta, the mode of delivery should be 719 
based on the clinical background, the woman’s preferences supplemented by ultrasound findings, 720 
including the distance between the placental edge and the fetal head position relative to the 721 
leading edge of the placenta on TVS. [D] 722 
 723 
Women presenting with a placental edge less than 20 mm from the internal os in the third trimester 724 
are more likely to need delivery by caesarean section when the placental edge is thicker (over 10 725 
mm)76,77 and/or contains a sponge-like echo78 or marginal ‘sinus’.79 These additional ultrasound 726 
features are poorly defined, not routinely assessed in UK practice and the success rates of vaginal 727 
delivery when the placental edge is between 10 and 20 mm from the internal os vary widely (56% 728 
and 93%, respectively).80–83 The corresponding studies are small, observational and retrospective, 729 
making a recommendation for a specific mode of delivery based on ultrasound findings difficult. 730 
[Evidence level 2–] 731 
 732 
5. Optimising the delivery of a placenta praevia 733 
 734 
Prior to delivery, all women with placenta praevia and their partners should have a discussion 735 
regarding delivery. Indications for blood transfusion and hysterectomy should be reviewed and 736 
concerns or plans to decline blood or blood products should be discussed openly and documented. 737 
[GPP]  738 
 739 
Placenta praevia and anterior low-lying placenta carry a higher risk of massive obstetric 740 
haemorrhage and hysterectomy. Delivery should be arranged in a maternity unit with on-site 741 
blood transfusion services and access to critical care. [D]  742 
Deleted: Late preterm (35+1 to 36+6 weeks of gestation) 743 
Deleted:  for women presenting with complicated placenta 744 
praevia or a low-lying placenta745 
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 748 
Women with atypical antibodies form a particularly high-risk group and the care of these women 749 
should involve discussions with the local haematologist and blood bank. [D] 750 
 751 
Prevention and treatment of anaemia during the antenatal period is recommended for women 752 
with placenta praevia or a low-lying placenta as for any pregnant woman. [D]  753 
 754 
General procedures for discussing and obtaining consent for caesarean section are described in 755 
detail in RCOG Consent Advice No.7: Caesarean section.84 [Evidence level 4] 756 
  757 
Women having a caesarean section for placenta praevia are at increased risk of blood loss of more 758 
than 1000 ml compared with women having a caesarean section for other indications (RR 3.97, 95% 759 
CI 3.24–4.85).85 Women with anterior placenta regardless of type of placenta praevia are at 760 
increased blood loss.86 Placenta praevia covering the internal cervical os and anterior placentation 761 
are independent risk factors (OR 4.1 and OR 3.5, respectively) for massive haemorrhage during 762 
caesarean section.86 A US case–control study from the National Institute of Child Health (NICH) and 763 
Human Development Maternal-Fetal Medicine Units (MFMU) Network Caesarean Section Registry 764 
has shown that maternal haemorrhagic morbidity is more common in women with praevia (19% 765 
versus 7%, adjusted RR 2.6, 95% CI 1.9-3.5) and the main factors associated with maternal 766 
haemorrhage include pre-delivery anaemia, thrombocytopenia, diabetes and magnesium use.87  767 
[Evidence level 2++] 768 
 769 
The risk of massive haemorrhage together with the possibility of needing a blood transfusion has 770 
been estimated to be approximately 12 times more likely in caesarean section for placenta praevia 771 
than in caesarean delivery for other indications.88,89 Similarly to uncomplicated pregnancies, women 772 
with placenta praevia should be screened for anaemia and investigated if their haemoglobin levels 773 
are outside the normal UK range (110 g/l at first visit and 105 g/l at 28 weeks).36 Iron 774 
supplementation should be implemented if indicated. [Evidence level 4] 775 
 776 
For women at high risk of emergency transfusion, such as those presenting with placenta praevia 777 
and with no clinically significant alloantibodies, it has been recommended that group and screen 778 
samples should be sent once a week to exclude or identify any new antibody formation and to keep 779 
blood available if necessary for delivery. However, this should be at the discretion of the team 780 
responsible and managed according to local facilitites.89 [Evidence level 4] 781 
 782 
6. Delivery for women with placenta praevia or a low-lying placenta 783 
 784 
6.1 What grade of obstetrician and anaesthetist should attend the caesarean delivery for a placenta 785 
praevia? 786 
 787 
As a minimum requirement for a planned caesarean section for placenta praevia, the surgical 788 
procedure should be carried out by an appropriately experienced operator. [GPP] 789 
 790 
In cases of planned caesarean section for placenta praevia or a low-lying placenta, a senior 791 
obstetrician (usually a consultant) and senior anaesthetist (usually a consultant) should be present 792 
within the delivery or theatre suite where the surgery is occurring. [GPP]  793 
 794 
When an emergency arises, the senior obstetrician and senior anaesthetist should be alerted 795 
immediately and attend urgently. [GPP]  796 
 797 
Maternal complications at caesarean section increase when the primary surgeon is a 798 
trainee/resident rather than an experienced surgeon.90 Placenta praevia is often associated with 799 
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additional including fetal malpresentation (transverse or breech presentation) requiring complex 800 
intraoperative manoeuvres to deliver the baby.91 [Evidence level 4] 801 
 802 
6.2 What anaesthetic procedure is most appropriate for caesarean section in placenta praevia? 803 
 804 
Regional anaesthesia is considered safe and associated with lower risks of haemorrhage than 805 
general anaesthesia for caesarean delivery in women with placenta praevia or a low-lying 806 
placenta. Women with anterior placenta praevia or a low-lying placenta should be advised that it 807 
may be necessary to convert to general anaesthesia if required and asked to consent. [D] 808 
 809 
There is insufficient evidence to support one technique over another and there have been no new 810 
trials since the previous version of this guideline.  811 
 812 
An RCT of regional versus general anaesthesia for placenta praevia, including women with placenta 813 
accreta, has indicated that blood transfusion requirements (although not estimated blood loss) are 814 
greater in the general anaesthetic group.92 [Evidence level 1–] 815 
 816 
A 4-year observational study at 19 US academic centres of women undergoing caesarean delivery 817 
found that the risk factors for haemorrhage-related morbidity are increased in those undergoing 818 
general anaesthesia.93 [Evidence level 2–]  819 
 820 
The recent case–control study from the NICHD/MFMU Network Cesarean Section Registry found 821 
general anaesthesia to be one of the main factors associated with maternal haemorrhage in women 822 
with placenta praevia.87 [Evidence level 2++] 823 
 824 
6.3 What blood products should be available? 825 
 826 
Close liaison with the hospital transfusion laboratory is essential for women presenting with 827 
placenta praevia or a low-lying placenta. [GPP] 828 
 829 
Rapid infusion and fluid warming devices should be immediately available. [GPP] 830 
 831 
Cell salvage is recommended for patients where the anticipated blood loss is great enough to 832 
induce anaemia, in particular, in women who would decline blood products. [D] 833 
 834 
Red cells, fresh frozen plasma, and cryoprecipitate or fibrinogen concentrate are all kept by blood 835 
banks supplying obstetric units. If the haemoglobin is less than 70 g/l in the postoperative period, 836 
where there is no ongoing or threat of bleeding, the decision to transfuse should be made on an 837 
informed individual basis.89 In an extreme situation and when the blood group is unknown, group O 838 
rhesus D-negative red cells should be given.89 Further recommendations are provided in Green-top 839 
Guideline No.52: Prevention and Management of Postpartum Haemorrhage. 88 [Evidence level 4] 840 
  841 
There is no evidence to support the use of autologous blood transfusion for placenta praevia.90 842 
[Evidence level 4] 843 
 844 
Cell salvage was not often used previously in obstetrics because of the perceived risk of amniotic 845 
fluid embolism or induction of maternal alloimmunisation. No definite cases of amniotic fluid 846 
embolism have been reported so far and the risks of cell salvage in the obstetric population parallel 847 
those in the non-pregnant population.94,95 [Evidence level 4] 848 
 849 
6.4 What surgical approach should be used for placenta praevia or a low-lying placenta? 850 
 851 
Consider vertical skin and/or uterine incisions when the fetus is in a transverse lie to avoid the 852 
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placenta, particularly below 28 weeks of gestation. [GPP] 853 
 854 
Consider using preoperative and/or intraoperative ultrasonography to precisely determine 855 
placental location and the optimal place for uterine incision. [D] 856 
 857 
If the placenta is transected during the uterine incision, immediately clamp the umbilical cord 858 
after fetal delivery to avoid excessive fetal blood loss. [D] 859 
 860 
If pharmacological measures fail to control haemorrhage, initiate intrauterine tamponade and/or 861 
surgical haemostatic techniques sooner rather than later. Interventional radiological techniques 862 
should also be urgently employed where possible. [C] 863 
 864 
Early recourse to hysterectomy is recommended if conservative medical and surgical interventions 865 
prove ineffective. [D]  866 
 867 
In cases of anterior placenta praevia, cutting through the placenta is often associated with increased 868 
maternal bleeding. A retrospective cohort study found that avoiding incision of the anterior placenta 869 
praevia after 24 weeks of gestation reduces the need for maternal blood transfusion during or after 870 
caesarean delivery.96 [Evidence level 2–] 871 
 872 
A ‘J’-shaped uterine incision has been evaluated in women presenting with placenta praevia in a 873 
small retrospective study and shown to decrease intraoperative blood loss and facilitate the delivery 874 
of the fetus.97 [Evidence level 2–] 875 
 876 
Intrauterine balloon tamponade, different types of compression sutures and uterine artery occlusion 877 
techniques have been increasingly used since the previous version of the guideline in women with 878 
placenta praevia to control, reduce or stop intraoperative bleeding and PPH. Case series on the use 879 
of intrauterine hydrostatic balloon catheters, including the Bakri balloon,98–102 the BT-Cath® 880 
balloon103 or the Sengstaken–Blakemore tube,104 in women with placenta praevia have reported 881 
success in controlling PPH ranging from 75% to 88%. [Evidence level 3] 882 
 883 
Factors associated with the failure of Bakri balloon tamponade for placenta praevia include prior 884 
caesarean section, anterior placentation, thrombocytopenia and/or coagulopathy at the time of 885 
insertion, and a PPH volume of more than 500 ml within the first hour of placement.100 [Evidence 886 
level 2++] 887 
 888 
Uterine compressive and endouterine sutures are well established techniques for the control of 889 
haemorrhage following atonic PPH. The best known suture technique was described by B-Lynch in 890 
1997.105 A combined method of B-Lynch suture and the intrauterine balloon has also been 891 
successfully used in preventing PPH in placenta praevia.106 [Evidence level 3] 892 
 893 
Intraoperative interventional radiological techniques, including transarterial embolisation107 and 894 
temporary balloon occlusion108 of the internal iliac arteries, have also been successfully used to 895 
prevent and control haemorrhage in placenta praevia and should be considered when available. 896 
Follow-up studies of women who have undergone arterial embolisation for control of PPH suggest 897 
that the intervention does not impair subsequent menstruation and fertility.109–111 [Evidence level 3] 898 
 899 
7. Antenatal diagnosis and outcome of placenta accreta spectrum 900 
 901 
7.1 What are the risk factors for placenta accreta spectrum? 902 
 903 
The major risk factors for placenta accreta spectrum are history of accreta in a previous 904 
pregnancy, previous caesarean delivery and other uterine surgery, including repeated endometrial 905 
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curettage. This risk rises as the number of prior caesarean sections increases. [B] 906 
 907 
Women requesting elective caesarean delivery for non-medical indications should be informed of 908 
the risk of placenta accreta spectrum and its consequences for subsequent pregnancies. [GPP] 909 
 910 
All epidemiological studies of the last 2 decades have shown a direct association between the 911 
increase in caesarean deliveries and the incidence of placenta accreta spectrum (abnormally 912 
adherent and invasive placenta) in subsequent pregnancies worldwide.112–122 The 2016 Nordic 913 
Obstetric Surveillance Study found that the risk of invasive placentation increases seven-fold after 914 
one prior caesarean section.118 [Evidence level 2+] 915 
 916 
A meta-analysis of five cohorts and 11 case–control studies reported a summary OR of 1.96 (95% CI 917 
1.41–2.74) for placenta accreta spectrum after a caesarean section.24 [Evidence level 2++] 918 
 919 
The risk of placenta accreta spectrum increases with the number of previous caesarean sections. A 920 
systematic review reported an increase in the incidence of accreta placentation from 3.3–4.0% in 921 
women with placenta praevia and no previous caesarean delivery, to 50–67% in women with three 922 
or more caesarean deliveries.25 When stratified for the number of previous caesarean sections, the 923 
OR for placenta accreta spectrum in a subsequent pregnancy ranges between 8.6 (95% CI 3.536–924 
21.078)112 and 17.4 (95% CI 9.0–31.4) for two previous caesarean sections, and 55.9 (95% CI 25.0–925 
110.3) for three or more caesarean sections.121 [Evidence level 2++] 926 
 927 
Placenta praevia is another important risk factor for placenta accreta spectrum (see Appendix II). A 928 
large multicentre US cohort study noted that for women presenting with placenta praevia and prior 929 
caesarean section the risk of accreta placentation was 3%, 11%, 40%, 61% and 67% for one, two, 930 
three, four, and five or more caesarean deliveries, respectively.113 The national case–control study 931 
using the UK Obstetric Surveillance System found that the incidence of placenta accreta spectrum 932 
increases from 1.7 per 10 000 women overall to 577 per 10 000 in women with both a previous 933 
caesarean section and placenta praevia.114 [Evidence level 2+] 934 
 935 
Other additional risk factors include maternal age111,114,118,121 and ART, in particular in vitro 936 
fertilisation.114,121,123–126 Advanced maternal age (35 years or more) in women without a previous 937 
caesarean section increases the aOR by 1.30 (95%CI 1.13-1.50) for every 1-year increase in age.114 938 
[Evidence level 2-] 939 
 940 
Placenta accreta spectrum is not exclusively a consequence of caesarean delivery. Other surgical 941 
trauma to the integrity of the uterine endometrium and/or superficial myometrium, such as those 942 
following uterine curettage, manual removal of the placenta, postpartum endometritis or 943 
myomectomy, has been associated with accreta placentation in subsequent pregnancies.1,12,13 944 
Overall, the aOR for placenta accreta spectrum after previous uterine surgery is 3.40 (95% CI 1.30–945 
8.91).114 [Evidence level 2+] 946 
 947 
The development of placenta accreta spectrum has also been reported in women with no surgical 948 
history but presenting with a uterine pathology, such as bicornuate uterus, adenomyosis, 949 
submucous fibroids and myotonic dystrophy.1,12,13 [Evidence level 3] 950 
 951 
More recently there has been an increase in reports describing implantation into deficient caesarean 952 
section scars and mounting evidence that a caesarean scar pregnancy diagnosed in early pregnancy 953 
can evolve into an abnormally adherent or invasive placenta in the second half of pregnancy.127–131 A 954 
caesarean scar pregnancy can be diagnosed using TVS from the second month of pregnancy using 955 
specific ultrasound criteria.130,131 In the last decade, the number of reported cases of caesarean scar 956 
pregnancy has increased due to improved awareness of the condition, widespread use of ultrasound 957 
scanning in early pregnancy and an increase in the number of prior caesarean sections. The outcome 958 
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of caesarean scar pregnancy depends on the amount of definitive placenta developing inside the 959 
scar and depth of villous invasion. Further data are required to establish the relationship between a 960 
first trimester scar pregnancy and the development of invasive placentation. [Evidence level 3] 961 
 962 
7.2 How can a placenta accreta spectrum be suspected and diagnosed antenatally? 963 
 964 
Antenatal diagnosis of placenta accreta spectrum is crucial in planning its management and has 965 
been shown to reduce maternal morbidity and mortality. [D] 966 
 967 
Previous caesarean delivery and the presence of an anterior low-lying placenta or placenta praevia 968 
should alert the antenatal care team of the higher risk of placenta accreta spectrum. [D] 969 
 970 
Maternal complications in placenta accreta spectrum are primarily the result of massive 971 
haemorrhage.5 Median estimated blood loss in cohorts of placenta accreta spectrum ranges from 972 
2000 to 7800 ml and the median number of units of blood transfused is 5 units.132 Antenatal 973 
diagnosis of placenta accreta spectrum reduces maternal peripartum haemorrhage and 974 
morbidity.20,133–136 [Evidence level 4] 975 
 976 
Population studies have shown that placenta accreta spectrum remains undiagnosed before delivery 977 
in one-half137 to two-thirds of cases.121 In a series from specialist centres, approximately one-third of 978 
cases of placenta accreta were not diagnosed during pregnancy.138 [Evidence level 2+] 979 
 980 
Multidisciplinary management in a maternity unit with access to maternal and neonatal intensive 981 
care is often required for women with placenta accreta spectrum.21,22,136,139 For such care to be 982 
organised, the diagnosis must be made antenatally. [Evidence level 4] 983 
 984 
7.2.1 Ultrasound screening and diagnosis of placenta accreta spectrum 985 
 986 
Ultrasound imaging is highly accurate when performed by a skilled operator with experience in 987 
diagnosing placenta accreta spectrum. [C] 988 
 989 
Refer women with any ultrasound features suggestive of placenta accreta spectrum to a specialist 990 
unit with imaging expertise. [B] 991 
 992 
Women with a history of previous caesarean section seen to have an anterior low-lying placenta 993 
or placenta praevia at the routine fetal anomaly scan should be specifically screened for placenta 994 
accreta spectrum. [D] 995 
 996 
Numerous ultrasound imaging techniques have been reported over the years, including greyscale 997 
imaging and colour Doppler imaging (CDI), and/or three-dimensional power Doppler 998 
sonography.16,17,140–142 In 2016, the European Working Group on Abnormally Invasive Placenta 999 
proposed a standardised description of ultrasound signs (see Appendix III) used for the prenatal 1000 
diagnosis of placenta accreta141 and the International Abnormally Invasive Placenta Expert Group 1001 
produced a proforma protocol for the ultrasound assessment.142 [Evidence level 4]  1002 
 1003 
A systematic review and meta-analysis of 23 ultrasound studies including 3707 pregnancies at risk of 1004 
placenta accreta found that the overall performance of ultrasound when performed by skilled 1005 
operators was very good with a sensitivity of 90.72% (95% CI 87.2–93.6), specificity of 96.94% (95% 1006 
CI 96.3–97.5) and diagnostic OR of 98.59 (95%CI 48.8–199.0). Among the different ultrasound signs, 1007 
abnormality of the uterus–bladder interface had the best specificity of 99.75% (95% CI 99.5–99.9) 1008 
for the prediction of placenta accreta. Abnormal vasculature on CDI had the best predictive accuracy 1009 
with a sensitivity of 90.74% (95% CI 85.2–94.7), specificity of 87.68% (95% CI 84.6–90.4) and 1010 
diagnostic OR of 69.02 (95% CI 22.8–208.9).143 [Evidence level 2++] 1011 
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 1012 
A 2017 systematic review and meta-analysis using the standardised ultrasound signs (see Appendix 1013 
III) has shown that in women presenting with placenta praevia and history of prior caesarean 1014 
section, the performance of ultrasound for the antenatal detection of placenta accreta spectrum is 1015 
even higher with a sensitivity of 97.0% (95% CI 93.0–99.0), specificity of 97.0% (95% CI 97.0–98.0) 1016 
and diagnostic OR of 228.5 (95% CI 67.2–776.9) in prospective studies.144 Placental lacunae give the 1017 
placenta a ‘moth-eaten’ appearance on greyscale imaging and the increased vascularity of the 1018 
placental bed with large feeder vessels entering the lacunae are the most common ultrasound signs 1019 
associated with placenta accreta spectrum.16,17,143,144 [Evidence level 2++] 1020 
 1021 
Determining the depth and lateral extension of placental invasion is helpful for planning the 1022 
individual care of women diagnosed with placenta accreta spectrum.16,17,145 No ultrasound sign or a 1023 
combination of ultrasound signs have so far been found to be specific to the depth of placenta 1024 
accreta spectrum and thus to provide with an accurate differential diagnosis between adherent and 1025 
invasive accreta placentation.16 This may be due to the wide heterogeneity in terminology used to 1026 
describe the grades of placenta accreta spectrum, differences in the study design with most studies 1027 
not reporting detailed data on clinical diagnosis at birth and/or on histopathology examination, and 1028 
many studies having included cases of placental retention in their cohort with no evidence of 1029 
abnormal villous adherence or invasion. [Evidence level 2++] 1030 
 1031 
As the vast majority of placenta accreta spectrum are now the consequence of low placentation into 1032 
a previous caesarean section scar, TVS has an important role in the early diagnosis, follow-up, 1033 
differential diagnosis between adherent and invasive accreta placentation and management of 1034 
placenta accreta spectrum.144 [Evidence level 4] 1035 
 1036 
7.2.2 Is there a role for magnetic resonance imaging (MRI) in the diagnosis of placenta accreta 1037 
spectrum? 1038 
 1039 
Clinicians should be aware that the diagnostic value of MRI and ultrasound imaging in detecting 1040 
placenta accreta spectrum is similar when performed by experts. [C] 1041 
 1042 
MRI may be used to complement ultrasound imaging to assess the depth of invasion and lateral 1043 
extension of myometrial invasion, especially with posterior placentation and/or in women with 1044 
ultrasound signs suggesting parametrial invasion. [GPP] 1045 
 1046 
MRI has been increasingly used for the prenatal diagnosis of placenta accreta.146–150 The main MRI 1047 
features of placenta accreta include abnormal uterine bulging, dark intraplacental bands on T2-1048 
weighted imaging, heterogeneous signal intensity within the placenta, disorganised vasculature of 1049 
placenta and disruption of the uteroplacental zone. A systematic review has found that most studies 1050 
are of a small sample size and thus, sensitivity and specificity of MRI in diagnosing placenta accreta 1051 
varies widely between 75% and 100%, and 65% and 100%, respectively.149 [Evidence level 2++] 1052 
 1053 
Two systematic reviews and meta-analyses have found that the diagnostic value of ultrasound 1054 
imaging and MRI in detecting placenta accreta spectrum is similar. The first review148 included 13 1055 
studies and reported a sensitivity of 83% (95% CI 77–88), specificity of 95% (95% CI 93–96) and 1056 
detection OR of 63.41 (95% CI 29.04–138.48) for ultrasound, compared with a sensitivity of 82% 1057 
(95% CI 72–90), specificity of 88% (95% CI 81–94) and detection OR of 22.95 (95% CI 3.19–165.11) 1058 
for MRI. The second review (2014)149 included 18 studies and found that the overall diagnostic 1059 
accuracy of MRI has a sensitivity of 94.4% (95% CI 86.0–97.9), specificity of 84.0% (95% CI 76.0–89.8) 1060 
and diagnostic OR of 89.0 (95% CI 22.8–348.1). The latter review also found that MRI has high 1061 
predictive accuracy in assessing both the depth and topography of placental invasion. [Evidence level 1062 
2++] 1063 
 1064 
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The use of intravenous gadolinium injection may increase the sensitivity and specificity of MRI in the 1065 
diagnosis of the invasive forms of placenta accreta spectrum but the evidence on long-term fetal 1066 
safety is limited.150 Furthermore, the experience of the radiologists remains an independent factor in 1067 
the diagnostic accuracy of MRI and access to expert radiologists is highly variable. [Evidence level 4] 1068 
 1069 
7.3 Where should women with placenta accreta spectrum be cared for? 1070 
 1071 
Women diagnosed with placenta accreta spectrum should be cared for by a multidisciplinary team 1072 
in a specialist centre with expertise in diagnosing and managing invasive placentation. [GPP] 1073 
 1074 
Delivery for women diagnosed with placenta accreta spectrum should take place in a specialist 1075 
centre with logistic support for immediate access to blood products, adult intensive care unit and 1076 
NICU by a multidisciplinary team with expertise in complex pelvic surgery. [D] 1077 
 1078 
More data have become available since the last version of this guideline on the specific management 1079 
of placenta accreta spectrum. Overall, women with accreta placentation should be cared for 1080 
according to the risks of severe maternal bleeding and premature delivery. Placenta percreta can be 1081 
associated with major prenatal complications from early in pregnancy, such as uterine rupture151–153 1082 
and bladder involvement with associated life-threatening haemorrhage.154–156 [Evidence level 4] 1083 
 1084 
A 2015 expert review has suggested that caesarean delivery of women at high risk and/or diagnosed 1085 
prenatally with placenta accreta spectrum, in particular its invasive forms, should occur in a 1086 
specialist centre with multidisciplinary expertise and experience in managing complex pelvic surgery, 1087 
and with access to an adult intensive care unit and NICU.136 [Evidence level 4] 1088 
 1089 
A retrospective cohort study of 77 women with suspected placenta accreta found that women who 1090 
delivered prior to a planned delivery date were significantly more likely to have had vaginal bleeding 1091 
and uterine activity when compared with women who had a scheduled delivery.20 Each episode of 1092 
antenatal vaginal bleeding is associated with an increased risk of unscheduled delivery (aOR 3.8, 95% 1093 
CI 1.8–7.8) and the risk increases when associated with preterm prelabour rupture of membranes. 1094 
[Evidence level 2–] 1095 
 1096 
Considering the higher frequency of placenta praevia in the accreta group,144,157 these results are 1097 
likely to be influenced by the perinatal complications of placenta praevia. Surveys of healthcare 1098 
providers in the US and Canada have highlighted widely varied approaches to virtually every aspect 1099 
of care for placenta accreta spectrum.158–161 Similarly, a recent online survey completed by members 1100 
of the expert panel for the perinatal management of placenta accreta spectrum disorders for the 1101 
International Federation of Gynecology and Obstetrics (FIGO) has found wide variation in global 1102 
practices.162 [Evidence level 4] 1103 
 1104 
There is increasing evidence from retrospective cohort studies from the USA that women with 1105 
placenta accreta spectrum diagnosed prenatally, cared for by a specialist multidisciplinary team, are 1106 
less likely to require large volume blood transfusion and reoperation within 7 days of delivery for 1107 
bleeding complications compared with women cared for by non-multidisciplinary standard obstetric 1108 
care without a specific protocol.21,22,136,139,163,164 Women admitted at 34 weeks of gestation and 1109 
delivered between 34 and 35 weeks of gestation by a specialist multidisciplinary team have a 1110 
significantly lower emergency surgery rate than those not cared for by such a team (23% versus 64%; 1111 
P = 0.001) despite a similar median gestational age at delivery (34 [16–39] weeks versus 34 [19-40] 1112 
weeks; P = 0.50, respectively).21 In addition, maternal outcomes are improved over time with 1113 
increasing experience within a well-established multidisciplinary team performing 2–3 cases per 1114 
month.22 Very few of these studies provide with data on the differential clinical diagnosis between 1115 
abnormally adherent and abnormally invasive accreta and detailed pathologic confirmation of the 1116 
depth and lateral extension of villous myometrial invasion. [Evidence level 2–] 1117 
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 1118 
7.4 When should delivery be planned for women with placenta accreta spectrum? 1119 
 1120 
In the absence of risk factors for preterm delivery and evidence of invasive placentation, planned 1121 
delivery at 35+0 to 36+6 weeks of gestation provides the best balance between fetal maturity and 1122 
the risk of unscheduled delivery. [GPP] 1123 
 1124 
Similarly to placenta praevia, clinical factors should be considered when determining the timing of 1125 
administration of antenatal corticosteroids and the optimal gestational age for delivery in women 1126 
with placental accreta.165,166 There are currently no RCTs or well-controlled observational studies to 1127 
guide best practice in delivery timing of placenta accreta spectrum. [Evidence level 4]  1128 
 1129 
In cases of suspected placenta accreta spectrum, where significant blood loss and caesarean 1130 
hysterectomy is anticipated, delivery at between 34 and 35 weeks of gestation has been proposed in 1131 
order to avoid emergency delivery, which still occurs about 20% of the time even in scheduled 1132 
cases.165,167 A 2010 decision analysis supports this approach based on the increasing likelihood of 1133 
emergency delivery as pregnancy goes beyond 34 weeks of gestation.168 [Evidence level 4] 1134 
 1135 
The data of three recent single institution retrospective cohort studies of women with prior 1136 
caesarean delivery diagnosed prenatally with placenta accreta have indicated that in the absence of 1137 
risk factors for preterm delivery, it is safe to plan the delivery at 36 weeks of gestation. The first 1138 
study included 103 women delivered between 1982 and 2002 and found that the mean gestational 1139 
age at delivery is 33+5 weeks of gestation in cases of deep placental invasion (increta and percreta) 1140 
compared with 35+2 weeks of gestation in the superficial adherent group.169 The second study of 216 1141 
women found that urgent delivery for bleeding decreased significantly with advancing gestation.170 1142 
Most women were delivered at 36 weeks of gestation or greater, with nearly 90% in the absence of 1143 
bleeding complications. The third study of 84 women who had reached 34+0 weeks of gestation with 1144 
a suspected praevia accreta found that those with no risk factors for preterm birth are at low risk for 1145 
an unscheduled delivery prior to 36 weeks of gestation.171 [Evidence level 2+] 1146 
 1147 
8. Planning delivery of a suspected placenta accreta spectrum 1148 
 1149 
Once the diagnosis of placenta accreta spectrum is made, a contingency plan for emergency 1150 
delivery should be developed, including the use of an institutional protocol for the management of 1151 
maternal haemorrhage. [GPP] 1152 
 1153 
Due to a lack of RCTs or well-controlled observational studies, the optimal management of placenta 1154 
accreta spectrum remains undefined and is determined by the expertise available, the depth and 1155 
lateral extension of the accreta portion of the placenta, the presence of an associated placenta 1156 
praevia, radiological findings, the medical and surgical comorbidities, and finally, the accessibility of 1157 
a regional team focused on these patients.  1158 
 1159 
The main risk associated with the delivery of placenta accreta spectrum is massive haemorrhage and 1160 
its associated complications, such as coagulopathy, multisystem organ failure and death. Many 1161 
women with placenta accreta spectrum require massive blood transfusion (8 units or more) and 1162 
their median platelet count is lowest compared with other causes of massive PPH.172,173 [Evidence 1163 
level 2+] 1164 
 1165 
A review of 34 studies published between 1977 and 2012, including a total number of 508 617 1166 
deliveries and 865 cases of confirmed placenta accreta, found that the most significant maternal 1167 
risks associated with delivery are the need for postpartum transfusion due to haemorrhage and 1168 
peripartum hysterectomy. Maternal mortality remains rare, but significantly higher than among 1169 
matched postpartum controls.123 [Evidence level 4] 1170 
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 1171 
Transfusions in placenta accreta spectrum should be guided by a national and/or institutional 1172 
protocol for management of PPH.88,89 [Evidence level 4] 1173 
 1174 
8.1 What should be included in the consent form for caesarean section in cases of suspected placenta 1175 
accreta spectrum? 1176 
 1177 
Any woman giving consent for caesarean section should understand the risks associated with 1178 
caesarean section in general, and the specific risks of placenta accreta spectrum in terms of 1179 
massive obstetric haemorrhage, increased risk of lower urinary tract damage, the need for blood 1180 
transfusion and the risk of hysterectomy. [GPP] 1181 
 1182 
Additional possible interventions in the case of massive haemorrhage should also be discussed, 1183 
including cell salvage and interventional radiology where available. [D] 1184 
 1185 
Any woman with suspected placenta accreta spectrum should meet with a senior obstetrician in the 1186 
antenatal period. The different risks and treatment options should have been discussed and a plan 1187 
agreed, which should be reflected clearly in the consent form and medical record. This should 1188 
include standard discussion for the caesarean section procedure84 and whether conservative 1189 
management of the placenta or proceeding straight to hysterectomy is preferred in the situation 1190 
where increta or percreta is confirmed at surgery. [Evidence level 4] 1191 
 1192 
Where available, cell salvage should be considered. If the woman refuses donor blood transfusion, it 1193 
is recommended89 that she be transferred to a unit with a cell saver. [Evidence level 4] 1194 
 1195 
8.2 What healthcare professionals should be involved? 1196 
 1197 
The elective delivery of women with placenta accreta spectrum should be managed by a 1198 
multidisciplinary team, which should include senior anaesthetists, obstetricians and 1199 
gynaecologists with appropriate experience in managing the condition and other surgical 1200 
specialties if indicated. In an emergency, the most senior clinicians available should be involved. 1201 
[GPP] 1202 
 1203 
Following the previous version of the guideline, the National Patient Safety Agency in collaboration 1204 
with the RCOG and the Royal College of Midwives set up an expert working group to develop a care 1205 
bundle for placenta accreta.174 Six elements of good care were agreed upon. The care bundle was 1206 
then tested in six units over a 5-month pilot study period and it was found to be both achievable and 1207 
practical. Clinical outcomes were monitored, confirming the high morbidity associated with this 1208 
condition. [Evidence level 4]  1209 
 1210 
The six elements considered to be reflective of good care are:  1211 
 1212 
• Consultant obstetrician planning and directly supervising delivery. 1213 
• Consultant anaesthetist planning and directly supervising anaesthesia at delivery.  1214 
• Blood and blood products available.  1215 
• Multidisciplinary involvement in preoperative planning.  1216 
• Discussion and consent, including possible interventions (such as hysterectomy, leaving the 1217 
placenta in situ, cell salvage and interventional radiology).  1218 
• Local availability of a level 2 critical care bed. 1219 
 1220 
The 2015 MBRRACE report from the Confidential Enquiry into Maternal Deaths in the UK has 1221 
indicated that despite increasing numbers of women at risk from placenta accreta spectrum 1222 
following previous caesarean section, only one death occurred in a woman who had a placenta 1223 
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praevia percreta and history of two previous caesarean sections.175 There were no deaths from 1224 
unexpected placenta accreta found at caesarean section, suggesting that previous recommendations 1225 
regarding imaging and preparations for women with placenta praevia and a previous caesarean 1226 
section have been followed.176 [Evidence level 2++]  1227 
 1228 
A 2015 single centre retrospective cohort study of the effectiveness of a standardised operative 1229 
approach in 98 cases of histologically confirmed placenta accreta supports the early presence of a 1230 
gynaecological surgeon and oncologist at delivery and demonstrates that a ‘call if needed’ approach 1231 
is not acceptable for these complex cases.177 [Evidence level 2+] 1232 
 1233 
The American College of Obstetricians and Gynecologists (ACOG) guidelines highlight that to 1234 
enhance patient safety, it is important that the delivery be performed by an experienced obstetric 1235 
team that includes an obstetric surgeon, with other surgical specialists, such as urologists, general 1236 
surgeons, and gynaecological surgeons and oncologists, available if necessary.166 [Evidence level 4] 1237 
 1238 
8.3 What anaesthetic is most appropriate for delivery? 1239 
 1240 
The choice of anaesthetic technique for caesarean section for placenta accreta spectrum should be 1241 
made by the anaesthetist conducting the procedure in consultation with the patient in advance. 1242 
[GPP] 1243 
 1244 
The woman should be informed that the surgical procedure can be performed safely with regional 1245 
anaesthesia but should be advised that it may be necessary to convert to general anaesthesia if 1246 
required and asked to consent. [D] 1247 
 1248 
Both general and regional anaesthetic techniques have been shown to be safe for surgical 1249 
procedures required for the delivery of placenta accreta spectrum; the judgment of which type of 1250 
technique to be used should be made on an individual basis.167 [Evidence level 4]  1251 
 1252 
There is insufficient evidence to support one technique over another and there have been no new 1253 
trials since the previous version of this guideline. 1254 
 1255 
8.4 Optimising the delivery of placenta accreta spectrum 1256 
 1257 
There are no RCTs comparing different surgical approaches for placenta accreta spectrum suspected 1258 
antenatally. Both conservative and radical surgical approaches can be associated with a high 1259 
maternal morbidity although the value of an experienced team in a specialist centre decreases the 1260 
risk significantly.21,22,136,139,163,164 [Evidence level 4]  1261 
 1262 
8.4.1 What surgical approach should be used for placenta accreta spectrum? 1263 
 1264 
Caesarean section hysterectomy with the placenta left in situ is preferable to attempting to 1265 
separate it from the uterine wall. [C] 1266 
 1267 
When the extent of the placenta accreta is limited in depth and surface area, and the entire 1268 
placental implantation area is accessible and visualised (i.e. completely anterior, fundal or 1269 
posterior without deep pelvic invasion), uterus-preserving surgery may be appropriate, including 1270 
partial myometrial resection. [GPP] 1271 
 1272 
Uterus-preserving surgical techniques should only be attempted by surgeons working in teams 1273 
with appropriate expertise to manage such cases and after appropriate counselling regarding risks 1274 
and with informed consent. [D] 1275 
 1276 
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There are currently insufficient data to recommend the routine use of ureteric stents in placenta 1277 
creta and increta. [C] 1278 
 1279 
The choice of surgical technique will depend on the position of the placenta, the depth of invasion, 1280 
and the parametrial extension of the placenta accreta spectrum as assessed by ultrasound and/or 1281 
MRI before delivery, the visual assessment of the uterus at the time of surgery and the presenting 1282 
clinical symptoms, i.e. bleeding or no bleeding.5 [Evidence level 4] 1283 
 1284 
The ACOG recommends planned, preterm caesarean section hysterectomy with the placenta left in 1285 
situ as removal of a placenta accreta spectrum is associated with significant haemorrhagic 1286 
morbidity.166 In cases of high suspicion for accreta during caesarean delivery, the majority of 1287 
members of the US Society of Maternal-Fetal Medicine (SMFM) and FIGO expert panel proceed with 1288 
hysterectomy.158–162 [Evidence level 4]  1289 
 1290 
Similarly, in a 2017 systematic review and meta-analysis on the diagnosis and outcome of placenta 1291 
accreta, an elective or emergency caesarean hysterectomy was performed in 208 out of 232 (89.7%) 1292 
cases.144 [Evidence level 2++] 1293 
 1294 
A retrospective study of 57 cases of suspected accreta demonstrated significantly reduced short-1295 
term morbidity if the placenta is left in place and hysterectomy performed electively compared with 1296 
attempting to remove the placenta first.178 Attempting placental separation risks hysterectomy in up 1297 
to 100% of cases as also confirmed by other authors.178,179 [Evidence level 2++] 1298 
 1299 
A case–control study of 49 women requiring a peripartum hysterectomy for massive haemorrhage, 1300 
including 20 women presenting with placenta accreta, reported that the use of a vessel sealing 1301 
device during surgery decreases the estimated blood loss, the need for massive blood transfusions, 1302 
and does not increase operative time or complication rates.180 [Evidence level 2+] 1303 
 1304 
A systematic review found that uterus-preserving surgery resulted in a secondary hysterectomy in 1305 
24/77 women (31%), maternal mortality in 2/55 women (4%), subsequent menstruation in 28/34 1306 
women (82%) and subsequent pregnancy in 19/26 women (73%).181 A more recent systematic 1307 
review showed that uterus-preserving surgery is associated with a success rate of 48/76 women 1308 
(63.2%), a secondary hysterectomy in 23/76 women (30.0%), maternal mortality in 2/54 women 1309 
(3.7%), subsequent menstruation in 20/37 women (81.1%) and subsequent pregnancy in 21/27 1310 
women (77.8%).182 [Evidence level 2++] 1311 
 1312 
A small cohort study has shown that the introduction of the Triple-P procedure (perioperative 1313 
placental localization, pelvic devascularization and placental non-separation) involving delivery of 1314 
the fetus via transverse uterine incision above the upper border of the placenta, myometrial excision 1315 
and reconstruction of the uterine wall reduces the rate of hysterectomy, PPH and duration of 1316 
hospital stay in women with placenta accreta.183 The incidence of post-operative complications of 1317 
the Triple-P procedure depends on comorbidities and in particular, the placental position and the 1318 
depth of villous invasion.184 Small case series have also reported on the successful use of 1319 
compression sutures and on using the cervix as a natural tamponade by inverting it into the uterine 1320 
cavity, and suturing the anterior and/or the posterior cervical lips into the anterior and/or posterior 1321 
walls of the lower uterine segment.185–188 [Evidence level 3] 1322 
 1323 
A systematic review of peripartum surgical techniques used in placenta accreta spectrum has found 1324 
that methotrexate (MTX) and uterus-preserving surgical techniques are associated with a 16% 1325 
unintentional urinary tract injury rate as opposed to 57% for standard hysterectomy and that use of 1326 
ureteric stents reduces the risk of urologic injury.189 [Evidence level 2++]  1327 
 1328 
There are no RCTs on the use of ureteric stents in placenta accreta spectrum. Ureteric stents or 1329 
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catheters are more commonly used pre-operatively in the USA where around 26% of the members 1330 
of both the SMFM159 and ACOG fellows161 are using them in the management of suspected of 1331 
abnormally invasive placenta. [Evidence level 4]  1332 
 1333 
8.4.2 What surgical approach should be used for placenta percreta? 1334 
 1335 
There is limited evidence to support uterus-preserving surgery in placenta percreta and women 1336 
should be informed of the high risk of peripartum and secondary complications, including the 1337 
need for secondary hysterectomy. [D] 1338 
 1339 
The following four approaches have been described.137,159–161,165,167,190 1340 
 1341 
1. Primary hysterectomy following delivery of the fetus, without attempting placental separation. 1342 
2. Delivery of the fetus avoiding the placenta, with repair of the incision leaving the placenta in 1343 
situ. 1344 
3. Delivery of the fetus without disturbing the placenta, followed by partial excision of the uterine 1345 
wall (placental implantation site) and repair of the uterus. 1346 
4. Delivery of the fetus without disturbing the placenta, and leaving it in situ, followed by elective 1347 
secondary hysterectomy 3–7 days following the primary procedure.  1348 
 1349 
There are no well-controlled observational studies, and therefore, no firm recommendations can be 1350 
made.  1351 
 1352 
Women with placenta percreta are more likely to require additional blood products and intensive 1353 
care admission than women with placenta creta or increta.190 The incidence of urological 1354 
complications is also increased, including cystotomy and ureteric injury.191 [Evidence level 4] 1355 
 1356 
When the urinary bladder is invaded by placental tissue, preoperative cystoscopy and the placement 1357 
of ureteric stents have been recommended.161,192 Planned cystotomy can prevent extensive 1358 
muscularis damage and bleeding from attempts at dissection.192 [Evidence level 4] 1359 
 1360 
Filling the bladder to identify the bladder separation site, opening the bladder to identify percreta 1361 
villous tissue and removal of the involved bladder area have also been recommended by different 1362 
authors.161,165,193 [Evidence level 4] 1363 
 1364 
Uterus-preserving surgery is possible in placenta percreta as demonstrated in a cohort study of 71 1365 
women. A multidisciplinary stepwise surgical approach, including bilateral ligations of the anterior 1366 
division of the iliac arteries before removing the placenta, was shown to be successful in controlling 1367 
the bleeding and preserving the patient's uterus in around 90% of the cases, with 14% of urinary 1368 
tract complications, most of which can be identified and repaired during caesarean section.194 1369 
[Evidence level 3] 1370 
 1371 
A review of 119 placenta percreta cases published in the international literature has shown that 1372 
expectant management with the placenta left in situ is associated with severe long-term 1373 
complications of haemorrhage and infections, including a 58% risk of secondary hysterectomy up to 1374 
9 months after the delivery. Local resection appears to be associated with fewer complications 1375 
within 24 hours postoperatively compared with hysterectomy or leaving the placenta in situ. 1376 
However, a selection bias in the direction of less severe cases for the local resection technique may 1377 
in part explain the lower complication rates with that approach.195 [Evidence level 4] 1378 
 1379 
8.5 Expectant management (leaving the placenta in situ) 1380 
 1381 
Elective peripartum hysterectomy may be unacceptable to women desiring uterine preservation 1382 
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or considered inappropriate by the surgical team. In such cases, leaving the placenta in situ should 1383 
be considered. [D] 1384 
 1385 
When the placenta is left in situ, local arrangements need to be made to ensure regular review, 1386 
ultrasound examination and access to emergency care should the woman experience 1387 
complications, such as bleeding or infection. [D] 1388 
 1389 
MTX adjuvant therapy should not be used for expectant management as it is of unproven benefit 1390 
and has significant adverse effects, including a reported maternal death. [C] 1391 
 1392 
Conservative management in placenta accreta spectrum, including in cases of placenta increta and 1393 
percreta, is an option in women who desire to preserve their fertility. However, it is not 1394 
recommended in women presenting with major bleeding as it is unlikely to be successful and risks 1395 
delaying definitive treatment and increasing morbidity.5 [Evidence level 4] 1396 
 1397 
A retrospective multicentre study examined 167 women treated conservatively for placenta accreta 1398 
in tertiary university hospital centres in France between 1993 and 2007. Conservative expectant 1399 
management with part of the placenta left in situ was successful in 131 out of 167 cases (78.4%; 95% 1400 
CI 71.4–84.4).196 One woman died of myelosuppression and nephrotoxicity related to MTX 1401 
administration through the umbilical cord. Spontaneous placental resorption occurred in 87 out of 1402 
116 cases (75.0%; 95% CI 66.1–82.6), with a median delay from delivery of 13.5 weeks (range 4–60 1403 
weeks).196 [Evidence level 2+] 1404 
 1405 
The patient should be warned of the risks of chronic bleeding, sepsis, septic shock, peritonitis, 1406 
uterine necrosis, fistula, injury to adjacent organs, acute pulmonary oedema, acute renal failure, 1407 
deep venous thrombosis or pulmonary embolism.196 Prophylactic antibiotics may be helpful in the 1408 
immediate postpartum period to reduce the risk of infective complications.197 [Evidence level 4] 1409 
 1410 
An observational case series, including 24 women with placenta accreta left in situ after delivery and 1411 
treated with MTX, reported placental delivery in 33.3% of the cases (spontaneously in 55%, and in 1412 
45% following dilatation and surgical evacuation).199 There was no control group of patients who did 1413 
not receive MTX and so it is unknown whether or not the MTX was clinically helpful. One patient did 1414 
suffer liver damage and the risks of this therapy must be balanced against the unproven benefit. 1415 
[Evidence level 3]  1416 
 1417 
The pattern of follow-up for the conservative management of placenta accreta spectrum is not 1418 
supported by RCTs and not stratified for the according to the depth and lateral extension of villous 1419 
myometrial invasion. Some authors have reported cases where retained villous tissues were 1420 
removed after conservative management using hysteroscopic resection200,201 or high-intensity 1421 
focused ultrasound.202 In rare cases, a disseminated intravascular coagulation may develop requiring 1422 
a secondary hysterectomy. 203 [Evidence level 3] 1423 
 1424 
8.6 When is interventional radiology indicated? 1425 
 1426 
Larger studies are necessary to determine the safety and efficacy of interventional radiology 1427 
before this technique can be advised in the routine management of placenta accreta spectrum. [D] 1428 
 1429 
Women diagnosed with placenta accreta spectrum who decline donor blood transfusion should be 1430 
managed in a unit with an interventional radiology service. [D] 1431 
 1432 
Since the publication of the last version of this guideline there have been several cohort studies 1433 
describing the use of interventional radiology in assisting surgical and conservative management of 1434 
placenta accreta with variable success. The main aim of this procedure is to reduce the risks of 1435 
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intraoperative haemorrhage during the caesarean delivery of pregnancies diagnosed antenatally 1436 
with praevia increta or percreta. Various combinations have been proposed, including intraoperative 1437 
internal iliac artery and/or postoperative uterine artery embolisation204,205 and internal iliac artery206–1438 
209 or abdominal balloon occlusion210–215. The latter technique has been increasingly used in China 1439 
but the methodology of these studies is very heterogeneous with no data on the diagnosis of the 1440 
different grades of villous invasion and variable confounding factors such as placental position and 1441 
number of previous caesarean deliveries. Small cohort studies have also been published on the use 1442 
of a tourniquet216,217 and of surgical artery ligation.218 [Evidence level 3] 1443 
 1444 
A single institution observational cohort study of 45 cases of placenta accreta describes the use of 1445 
prophylactic lower abdominal aorta balloon occlusion and found a reduced need for blood 1446 
transfusion.212 One of the cases was complicated by lower extremity arterial thrombosis and another 1447 
by ischaemic injury to the femoral nerve. A comparative study of abdominal aortic occlusion versus 1448 
internal iliac artery occlusion found that aortic balloon occlusion resulted in better clinical outcomes 1449 
with less blood loss, blood transfusion, balloon insertion time, fluoroscopy time and fetal radiation 1450 
dose.215 [Evidence level 2–]  1451 
 1452 
A systematic review reported success rates of 159/177 (89.8%) for arterial embolisation, with 1453 
secondary hysterectomy being necessary in 20/177 (11.3%) and subsequent menstruation occurring 1454 
in 74/85 (87.1%). In 3/10 women (30%) a subsequent pregnancy occurred. Arterial balloon occlusion 1455 
catheters have been associated with a success rate of 33/42 (78.6%) and the need for a secondary 1456 
hysterectomy in 8/42 (19%).182 [Evidence level 2++] 1457 
 1458 
The value of prophylactic placement of balloon catheters in the iliac arteries in cases of placenta 1459 
accreta has been more controversial. This is mainly because of the higher risks of complications than 1460 
embolisation, including iliac artery thrombus or rupture, and ischaemic nerve injury.219–222 [Evidence 1461 
level 3] 1462 
 1463 
A small RCT of women presenting with a prenatal diagnosis of placenta accreta was published in 1464 
2015.223 The women were randomised to either preoperative prophylactic balloon catheters (n = 13) 1465 
or to a control group (n = 14). No difference was observed for the number of women with blood loss 1466 
greater than 2500 ml, number of plasma products transfused, duration of surgery, peripartum 1467 
complications and hospitalisation length. Reversible adverse effects related to prophylactic balloon 1468 
catheter insertion were noted in 2/13 (15.4%) cases. [Evidence level 1+] 1469 
 1470 
8.7 How is unsuspected placenta accreta spectrum at delivery best managed? 1471 
 1472 
If at the time of an elective repeat caesarean section, where both mother and baby are stable, it is 1473 
immediately apparent that placenta percreta is present on opening the abdomen, the caesarean 1474 
section should be delayed until the appropriate staff and resources have been assembled and 1475 
adequate blood products are available. This may involve closure of the maternal abdomen and 1476 
urgent transfer to a specialist unit for delivery. [GPP] 1477 
 1478 
In case of unsuspected placenta accreta spectrum diagnosed after delivery of the baby, the 1479 
placenta should be left in situ and an emergency hysterectomy performed. [D]  1480 
 1481 
If the placenta fails to separate with the usual measures, leaving it in place and closing, or leaving it 1482 
in place, closing the uterus and proceeding to a hysterectomy are both associated with less blood 1483 
loss than trying to separate it. Attempts at removing placenta accreta at caesarean section can lead 1484 
to massive haemorrhage, high maternal morbidity and possible maternal death. These risks are 1485 
particularly high when the caesarean section takes place in an environment with no emergency 1486 
access to blood bank products and expertise in managing placenta accreta.20,21,123,136 [Evidence level 1487 
4] 1488 
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 1489 
9. Clinical governance 1490 
 1491 
9.1 Debriefing 1492 
 1493 
Postnatal follow-up should include debriefing with an explanation of what happened, why it 1494 
happened and any implications for future pregnancy or fertility. In particular, women where 1495 
conservative treatment of placenta accreta spectrum has been successful should be informed of the 1496 
risk of recurrence.  1497 
 1498 
9.2 Training 1499 
 1500 
Raising the awareness about the clinical risk factors of placenta accreta spectrum should be pursued 1501 
locally, including organising policies or guidelines for flagging up women at risk and arranging for 1502 
them to see a specialist consultant when suspected. 1503 
 1504 
There should be appropriate training for ultrasound staff in the antenatal diagnosis of placenta 1505 
accreta spectrum.  1506 
 1507 
9.3 Clinical incident reporting 1508 
 1509 
Any lack of compliance with the care bundle by the clinical team for a woman with either placenta 1510 
praevia or accreta should be investigated.  1511 
 1512 
There should be written protocols for identification of and planning further care of women 1513 
suspected to have placenta accreta spectrum.  1514 
 1515 
10. Recommendations for future research 1516 
 1517 
• A large prospective study comparing the impact on the management of the use of the ’low-lying 1518 
placenta or placenta praevia’ classification with the traditional grades 1–4 classification at 1519 
different gestations is needed. 1520 
• Prospective studies are needed to assess the role of third trimester ultrasound in evaluating the 1521 
risks of haemorrhage and emergency caesarean section in low-lying placenta and determining 1522 
the mode of delivery. 1523 
• Large prospective population-based studies are needed in order to assess whether ultrasound is 1524 
a cost-effective screening tool for placenta accreta spectrum in women with a history of 1525 
caesarean section(s) presenting with a low-lying placenta or placenta praevia in the second 1526 
trimester of pregnancy. 1527 
• Prospective comparative ultrasound imaging including transvaginal ultrasound and MRI studies 1528 
are needed to evaluate the diagnostic accuracy for evaluation of the depth and topography of 1529 
villous invasion in adjacent organs.  1530 
• RCTs of optimal timing of delivery for both conditions (placenta praevia and placenta accreta) 1531 
are needed. 1532 
• RCTs of surgical and nonsurgical management strategies for placenta accreta spectrum 1533 
(including interventional radiology) and comparing conventional versus conservative 1534 
management, stratified according to the depth and lateral extension of villous myometrial 1535 
invasion, are needed. 1536 
• Future studies on the diagnosis and management of placenta accreta spectrum should use 1537 
standardised evidence-based approach including a systematic correlation between ultrasound 1538 
signs and detailed clinical diagnosis at delivery and pathologic confirmation of grades of villous 1539 
invasiveness when possible. 1540 
 1541 
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11. Auditable topics 1542 
 1543 
Placenta praevia 1544 
 1545 
• Antenatal diagnosis of placenta praevia (100%). 1546 
• Antenatal detection and treatment of anaemia (100%). 1547 
• Antenatal imaging performed according to hospital policy (100%). 1548 
• Appropriate antenatal delivery plan made and documented, to include discussion with woman 1549 
and her partner, documentation that the risks and indications for blood transfusion and 1550 
hysterectomy have been discussed and that concerns, queries or refusals of treatments have 1551 
been addressed (100%). 1552 
• Involvement of local blood bank and haematologist in the care of women with placenta praevia 1553 
and atypical antibodies (100%). 1554 
• Appropriate personnel present at delivery (100%). 1555 
• Appropriate site for delivery (100%). 1556 
• Appropriate surgical approaches performed (100%). 1557 
• Early-term elective delivery between 37+0 and 37+6 weeks of gestation for asymptomatic women 1558 
with placenta praevia and no other risk factors (100%). 1559 
• Antenatal steroid administration between 34+0 and 36+0 weeks of gestation (100%). 1560 
• Women requesting elective caesarean section for nonmedical reasons are informed of the risk of 1561 
placenta praevia and accreta spectrum, and its consequences in future deliveries (100%). 1562 
 1563 
Placenta accreta spectrum 1564 
 1565 
• Antenatal imaging performed according to hospital policy with diagnosis confirmed at birth 1566 
(100%). 1567 
• Appropriate antenatal delivery plan made and documented, to include discussion with woman 1568 
and her partner, documentation that the risks and indications for blood transfusion and 1569 
hysterectomy have been discussed and that concerns, queries or refusals of treatments have 1570 
been addressed (100%). 1571 
• All elements of the care bundle satisfied before elective surgery in women with placenta accreta 1572 
spectrum (100%): 1573 
o consultant obstetrician planned and directly supervising delivery 1574 
o consultant anaesthetist planned and directly supervising anaesthetic at delivery 1575 
o blood and blood products available 1576 
o multidisciplinary involvement in preoperative planning 1577 
o discussion and consent includes possible interventions (such as hysterectomy, leaving the 1578 
placenta in place, cell salvage and interventional radiology) and local availability of a level 2 1579 
critical care bed. 1580 
 1581 
12. Useful links and support groups 1582 
 1583 
• Royal College of Obstetricians and Gynaecologists. Low-lying placenta after 20 weeks (placenta 1584 
praevia). Information for you. London: RCOG; 20XX [insert web address]. 1585 
• National Childbirth Trust. Placenta praevia – low-lying placenta 1586 
[https://www.nct.org.uk/pregnancy/low-lying-placenta]. 1587 
 1588 
 1589 
 1590 
 1591 
 1592 
 1593 
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Appendix I: Explanation of guidelines and evidence levels 2174 
 2175 
Clinical guidelines are: ‘systematically developed statements which assist clinicians and patients in 2176 
making decisions about appropriate treatment for specific conditions’. Each guideline is 2177 
systematically developed using a standardised methodology. Exact details of this process can be 2178 
found in Clinical Governance Advice No.1 Development of RCOG Green-top Guidelines (available on 2179 
the RCOG website at http://www.rcog.org.uk/green-top-development). These recommendations are 2180 
not intended to dictate an exclusive course of management or treatment. They must be evaluated 2181 
with reference to individual patient needs, resources and limitations unique to the institution and 2182 
variations in local populations. It is hoped that this process of local ownership will help to 2183 
incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty 2184 
where further research may be indicated.  2185 
 2186 
The evidence used in this guideline was graded using the scheme below and the recommendations 2187 
formulated in a similar fashion with a standardised grading scheme. 2188 
 2189 
Classification of evidence levels  2190 
1++ High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised 
controlled trials with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews of randomised controlled trials or 
randomised controlled trials with a low risk of bias 
1– Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled 
trials with a high risk of bias 
2++ High-quality systematic reviews of case–control or cohort studies or high-quality 
case–control or cohort studies with a very low risk of confounding, bias or chance and a 
high probability that the relationship is causal 
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance 
and a moderate probability that the relationship is causal 
2– Case–control or cohort studies with a high risk of confounding, bias or chance and a 
significant risk that the relationship is not causal 
3 Non-analytical studies, e.g. case reports, case series 
4 Expert opinion 
 2191 
Grades of Recommendation 2192 
At least one meta-analysis, systematic reviews or RCT rated as 1++, and directly applicable to 2193 
the target population; or a systematic review of RCTs or a body of evidence consisting 2194 
principally of studies rated as 1+, directly applicable to the target population and 2195 
demonstrating overall consistency of results 2196 
 2197 
A body of evidence including studies rated as 2++ directly applicable to the target 2198 
population, and demonstrating overall consistency of results; or  2199 
 Extrapolated evidence from studies rated as 1++ or 1+ 2200 
 2201 
A body of evidence including studies rated as 2+ directly applicable to the target population, 2202 
and demonstrating overall consistency of results; or  2203 
 Extrapolated evidence from studies rated as 2++ 2204 
 2205 
 Evidence level 3 or 4; or  2206 
 Extrapolated evidence from studies rated as 2+  2207 
 2208 
Good Practice Points 2209 
 2210 
  Recommended best practice based on the clinical experience of the guideline development 2211 
A 
B 
C 
ü 
D 
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  group 2212 
 2213 
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Appendix II: Flow diagram for ultrasound diagnosis and follow-up of placenta praevia and placenta accreta spectrum 2214 
 2215 
 2216 
Abbreviations: BMI body mass index; PAS placenta accreta spectrum; TAS transabdominal scan; TVS transvaginal scan. 2217 
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Appendix III: Ultrasound imaging signs commonly used to diagnose placenta accreta spectrum (modified from Collins SL)141  2218 
 2219 
Ultrasound imaging signs Description  
2D greyscale signs 
Loss of the ‘clear zone’ Loss or irregularity of the hypoechoic plane in the myometrium underneath the placental bed (the ‘clear zone’). 
Abnormal placental lacunae Presence of numerous lacunae, including some that are large and irregular (Finberg grade 3), often containing turbulent flow visible 
in greyscale imaging.  
Bladder wall interruption Loss or interruption of the bright bladder wall (the hyperechoic band or ‘line’ between the uterine serosa and the bladder lumen). 
Myometrial thinning Thinning of the myometrium overlying the placenta to less than 1 mm or undetectable. 
Placental bulge Deviation of the uterine serosa away from the expected plane, caused by an abnormal bulge of placental tissue into a 
neighboring organ, typically the bladder. The uterine serosa appears intact but the outline shape is distorted. 
Focal exophytic mass Placental tissue seen breaking through the uterine serosa and extending beyond it. Most often seen inside a filled urinary bladder. 
 
2D colour Doppler signs  
Uterovesical hypervascularity Striking amount of colour Doppler signal seen between the myometrium and the posterior wall of the bladder. This sign probably 
indicates numerous, closely packed, tortuous vessels in that region (demonstrating multidirectional flow and aliasing artifact). 
Subplacental hypervascularity Striking amount of colour Doppler signal seen in the placental bed. This sign probably indicates numerous, closely packed, tortuous 
vessels in that region (demonstrating multidirectional flow and aliasing artifact). 
Bridging vessels Vessels appearing to extend from the placenta, across the myometrium and beyond the serosa into the bladder or other organs. 
Often running perpendicular to the myometrium. 
Placental lacunae feeder vessels Vessels with high velocity blood flow leading from the myometrium into the placental lacunae, causing turbulence upon entry. 
 
3D colour Doppler signs 
Intraplacental hypervascularity 
(power Doppler) 
 
Complex, irregular arrangement of numerous placental vessels, exhibiting tortuous courses and varying calibers. 
 2220 
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The guideline will be considered for update 3 years after publication, with an intermediate assessment of the need 2253 
to update 2 years after publication. 2254 
 2255 
 2256 
DISCLAIMER 2257 
 2258 
The Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical 2259 
practice. They present recognised methods and techniques of clinical practice, based on published evidence, for 2260 
consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement 2261 
regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the 2262 
light of clinical data presented by the patient and the diagnostic and treatment options available. 2263 
 2264 
This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to 2265 
be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or 2266 
guidelines should be fully documented in the patient’s case notes at the time the relevant decision is taken. 2267 
